<SEC-DOCUMENT>0001811884-24-000018.txt : 20240809
<SEC-HEADER>0001811884-24-000018.hdr.sgml : 20240809
<ACCEPTANCE-DATETIME>20240809160604
ACCESSION NUMBER:		0001811884-24-000018
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240809
DATE AS OF CHANGE:		20240809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		241192595

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20240630.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://www.utahmed.com/20240630" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D240101_240630" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="D240101_240630" id="fact2">--12-31</ix:nonNumeric>
<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="D240101_240630" id="fact3">Yes</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D240101_240630" id="fact4">false</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="D240101_240630" id="fact5">2024</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="D240101_240630" id="fact6">Q2</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20240630.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:unit id="USD">
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id="Shares">
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id="UsdPerShare">
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
<i:unit id="Pure">
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:context id="D240101_240630">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="E24Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E23Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id="I240808">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-08-08</i:instant>
</i:period>
</i:context>
<i:context id="E23">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-04-01</i:startDate>
<i:endDate>2023-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D230101_230630">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="E22">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E24Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E22_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E22_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E22_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E22_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y23Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E23Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E23Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E23Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E23Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E23Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="Y23Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-04-01</i:startDate>
<i:endDate>2023-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-04-01</i:startDate>
<i:endDate>2023-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-04-01</i:startDate>
<i:endDate>2023-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-04-01</i:startDate>
<i:endDate>2023-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="E23Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E23Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E23Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E23Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-06-30</i:instant>
</i:period>
</i:context>
<i:context id="D240101_240630_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-Obstetrics">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-Obstetrics_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-Obstetrics_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-Obstetrics">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-Neonatal">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-Neonatal_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-Neonatal_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-Neonatal">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-Obstetrics_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-Obstetrics_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-Neonatal_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-Neonatal_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="D240701_240808">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-07-01</i:startDate>
<i:endDate>2024-08-08</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">UNITED STATES</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Washington, D.C. &#160;20549</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>FORM </b><ix:nonNumeric name="dei:DocumentType" contextRef="D240101_240630" escape="true" id="ixv-5768">10-Q</ix:nonNumeric></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><span style="font-family:MS Gothic"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="D240101_240630" format="ixt-sec:boolballotbox" id="ixv-5769">&#9746;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D240101_240630" format="ixt:date-monthname-day-year-en" id="ixv-5770"> June 30, 2024</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">OR</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><span style="font-family:MS Gothic"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="D240101_240630" format="ixt-sec:boolballotbox" id="ixv-5771">&#9744;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the transition period from  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Commission File No. <span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D240101_240630" escape="true" id="ixv-5772">001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D240101_240630" escape="true" id="ixv-5773">UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(Exact name of Registrant as specified in its charter)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D240101_240630" format="ixt-sec:stateprovnameen" id="ixv-5774">Utah</ix:nonNumeric></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D240101_240630" escape="true" id="ixv-5775">87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of incorporation or organization)</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D240101_240630" escape="true" id="ixv-5776">7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D240101_240630" escape="true" id="ixv-5777">Midvale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D240101_240630" format="ixt-sec:stateprovnameen" id="ixv-5778">Utah</ix:nonNumeric> &#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D240101_240630" escape="true" id="ixv-5779">84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="D240101_240630" escape="true" id="ixv-5780">801</ix:nonNumeric>) </span><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D240101_240630" escape="true" id="ixv-5781">566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Title of each class:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Trading Symbol:</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="D240101_240630" escape="true" id="ixv-5782">Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="D240101_240630" escape="true" id="ixv-5783">UTMD</ix:nonNumeric></p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="D240101_240630" id="ixv-5784">NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<span style="-sec-ix-hidden:fact3">Yes</span>&#160;<span style="font-family:MS Gothic">&#9746;</span> &#160;&#160;No&#160;<span style="font-family:MS Gothic">&#9744;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="D240101_240630" id="ixv-5785">Yes</ix:nonNumeric>&#160;<span style="font-family:MS Gothic">&#9746;</span> &#160;&#160;No&#160;<span style="font-family:MS Gothic">&#9744;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Large accelerated filer&#160;<span style="font-family:MS Gothic">&#9744;</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Accelerated filer&#160;<span style="font-family:MS Gothic">&#9744;</span></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="D240101_240630" format="ixt-sec:entityfilercategoryen" id="ixv-5786">Non-accelerated filer</ix:nonNumeric> <span style="font-family:MS Gothic">&#9746;</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Smaller reporting company <span style="font-family:MS Gothic"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="D240101_240630" format="ixt-sec:boolballotbox" id="ixv-5787">&#9746;</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Emerging growth company <span style="font-family:MS Gothic"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D240101_240630" format="ixt-sec:boolballotbox" id="ixv-5788">&#9744;</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:MS Gothic">&#9744;</span> &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<span style="font-family:MS Gothic"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="D240101_240630" format="ixt-sec:boolballotbox" id="ixv-5789">&#9744;</ix:nonNumeric></span> &#160;&#160;No&#160;<span style="font-family:MS Gothic">&#9746;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of August 8, 2024: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="I240808" decimals="INF" unitRef="Shares" scale="0" format="ixt:num-dot-decimal" id="ixv-5790">3,477,117</ix:nonFraction>.&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a1"></a><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">INDEX TO FORM 10-Q</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">PAGE</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">PART I - FINANCIAL INFORMATION</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">Item 1.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">Financial Statements</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a5" style="text-decoration:none">Consolidated Condensed Balance Sheets as of June 30, 2024 and December 31, 2023</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">1</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a6" style="text-decoration:none">Consolidated Condensed Statements of Income for the three and six months ended June 30, 2024 and June 30, 2023</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">2</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a7" style="text-decoration:none">Consolidated Condensed Statements of Cash Flows for the six months ended June 30, 2024 and June 30, 2023</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">3</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a8" style="text-decoration:none">Consolidated Condensed Statements of Stockholders&#8217; Equity for the three and six months ended June 30, 2024 and June 30, 2023</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">4</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a9" style="text-decoration:none">Notes to Consolidated Condensed Financial Statements</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">5</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a10" style="text-decoration:none">Item 2.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a10" style="text-decoration:none">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">7</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a11" style="text-decoration:none">Item 3.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a11" style="text-decoration:none">Quantitative and Qualitative Disclosures About Market Risk</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a12" style="text-decoration:none">Item 4.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a12" style="text-decoration:none">Controls and Procedures</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a13" style="text-decoration:none">PART II &#8211;&#160;OTHER INFORMATION</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a14" style="text-decoration:none">Item 1.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a14" style="text-decoration:none">Legal Proceedings</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">16</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a15" style="text-decoration:none">Item 1A.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a15" style="text-decoration:none">Risk Factors</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">16</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a16" style="text-decoration:none">Item 2.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a16" style="text-decoration:none">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">17</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a17" style="text-decoration:none">Item 6.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a17" style="text-decoration:none">Exhibits</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">18</p>
</td></tr>
<tr><td valign="top" style="width:19.12%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a18" style="text-decoration:none">SIGNATURES</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%"><p style="font:10pt Times New Roman;margin:0;text-align:center">18</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a4"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">PART I - FINANCIAL INFORMATION</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><b>Item 1. Financial Statements</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a5"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.75pt"><td colspan="4" valign="bottom" style="width:473.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="4" valign="bottom" style="width:473.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style="height:8.25pt"><td colspan="4" valign="bottom" style="width:473.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">JUNE 30, 2024 AND DECEMBER 31, 2023</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="4" valign="bottom" style="width:473.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands)</p>
</td></tr>
<tr style="height:21pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(unaudited)</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(audited)</p>
</td></tr>
<tr style="height:19.5pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"/><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">JUNE 30, 2024</span></p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">DECEMBER 31, 2023</span></p>
</td></tr>
<tr style="height:19.5pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><span style="border-bottom:1px solid #000000">ASSETS</span></p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Current assets:</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Cash &amp; investments</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5791">89,219</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5792">92,868</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accounts &amp; other receivables, net</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5793">3,668</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5794">3,391</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Inventories</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5795">9,058</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5796">9,582</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Other current assets</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5797">377</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5798">428</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total current assets</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5799">102,322</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5800">106,269</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment, net</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5801">10,194</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5802">10,551</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Goodwill</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5803">13,640</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5804">13,692</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Other intangible assets</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5805">54,030</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5806">54,296</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Other intangible assets - accumulated amortization</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5807">50,154</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5808">49,350</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets, net</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5809">3,876</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5810">4,946</ix:nonFraction></p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total assets</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:Assets" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5811">130,032</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:Assets" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5812">135,458</ix:nonFraction></p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><span style="border-bottom:1px solid #000000">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Current liabilities:</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accounts payable</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5813">834</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5814">769</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accrued expenses</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5815">3,105</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5816">3,941</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total current liabilities</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5817">3,939</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5818">4,710</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Deferred tax liability &#8211; Femcare IIA</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5819">860</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5820">1,120</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Other long term liabilities</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5821">698</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5822">698</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Operating lease liability</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5823">275</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5824">295</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Deferred income taxes</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5825">208</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5826">322</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total liabilities</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5827">5,980</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5828">7,145</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Stockholders' equity:</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Common stock - $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5829"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E23" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5830">0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5831"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E23" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5832">50,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding - June 30, 2024, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5833"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5834">3,499</ix:nonFraction></ix:nonFraction> shares and December 31, 2023, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E23" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5835"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E23" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5836">3,630</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5837">35</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5838">36</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accumulated other comprehensive loss</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E24Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5839">11,322</ix:nonFraction>)</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E23" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5840">10,658</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Additional paid-in capital</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E24Q2" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5841">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5842">594</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Retained earnings</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5843">135,339</ix:nonFraction> </p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5844">138,341</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total stockholders' equity</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5845">124,052</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5846">128,313</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:209.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total liabilities and stockholders' equity</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:116.35pt;padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5847">130,032</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:130.55pt;padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5848">135,458</ix:nonFraction></p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="width:209.05pt;padding-right:5.75pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:116.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:17.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:130.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">1</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a6"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.75pt"><td colspan="9" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="9" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="9" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND JUNE 30, 2023</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="9" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands, except per share amounts - unaudited)</p>
</td></tr>
<tr style="height:12.75pt"><td colspan="9" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three Months Ended </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six Months Ended </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30, 2024</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30, 2023</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30, 2024</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30, 2023</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"/><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000"/><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000"/><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000"/><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000"/></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Sales, net</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5849">10,400</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5850">12,866</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5851">21,740</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5852">25,386</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Cost of goods sold</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5853">4,147</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5854">5,127</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5855">8,722</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5856">9,805</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Gross profit</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5857">6,253</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5858">7,739</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5859">13,018</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5860">15,581</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Operating expense</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Selling, general and administrative</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5861">2,560</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5862">3,181</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5863">5,176</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5864">6,440</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Research &amp; development</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5865">255</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5866">133</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5867">521</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5868">277</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total operating expenses</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5869">2,815</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5870">3,314</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5871">5,697</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5872">6,717</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Operating income</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5873">3,438</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5874">4,425</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5875">7,321</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5876">8,864</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Other income</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5877">773</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5878">747</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5879">1,689</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5880">1,428</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Income before provision for income taxes</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5881">4,211</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5882">5,172</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5883">9,010</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5884">10,292</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5885">758</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5886">972</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5887">1,601</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5888">1,878</ix:nonFraction> </p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Net income</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5889">3,453</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5890">4,200</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5891">7,409</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5892">8,414</ix:nonFraction> </p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (basic)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5893">0.98</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y23Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5894">1.16</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D240101_240630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5895">2.07</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D230101_230630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5896">2.32</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (diluted)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5897">0.98</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y23Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5898">1.15</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D240101_240630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5899">2.07</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D230101_230630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5900">2.31</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding - basic</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5901">3,532</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y23Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5902">3,628</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D240101_240630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5903">3,579</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D230101_230630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5904">3,628</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding - diluted</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5905">3,532</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y23Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5906">3,639</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D240101_240630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5907">3,579</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D230101_230630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5908">3,638</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Other comprehensive income (loss):</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:23.25pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Foreign currency translation net of taxes of $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y24Q2" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-5909"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y23Q2" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-5910"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="D240101_240630" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-5911"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="D230101_230630" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-5912">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5913">33</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5914">504</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5915">664</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5916">1,053</ix:nonFraction></p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total comprehensive income</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5917">3,420</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5918">4,704</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5919">6,745</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5920">9,467</ix:nonFraction> </p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;margin-left:38.9pt">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">2</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a7"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.75pt"><td colspan="5" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="5" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="5" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND JUNE 30, 2023</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="5" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands - unaudited)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six Months Ended<br/>June 30,</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"/><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5921">7,409</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5922">8,414</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Adjustments to reconcile net income to net<br/> &#160;cash provided by operating activities</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Depreciation</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5923">327</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5924">310</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Amortization</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5925">1,023</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5926">3,207</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;margin-left:10.1pt"><span style="font-family:Times New Roman">Provision for (recovery of) losses on accounts receivable</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5927">6</ix:nonFraction>) </span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D230101_230630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5928">26</ix:nonFraction>) </span></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Amortization of Right-of-Use Assets</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5929">26</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5930">26</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;margin-left:10.1pt"><span style="font-family:Times New Roman">Deferred income taxes</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5931">364</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="D230101_230630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5932">137</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Stock-based compensation expense</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5933">131</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5934">100</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Tax benefit attributable to exercise of stock options</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5935">20</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5936">9</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Changes in operating assets and liabilities:</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accounts receivable and other receivables</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5937">297</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D230101_230630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5938">2,044</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Inventories</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5939">441</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5940">1,245</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Prepaid expenses and other current assets</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5941">45</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D230101_230630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5942">3</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accounts payable</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5943">66</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5944">114</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accrued expenses</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5945">783</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="D230101_230630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5946">991</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total adjustments</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5947">629</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5948">3,414</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Net cash provided by operating activities</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5949">8,038</ix:nonFraction> </span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5950">11,828</ix:nonFraction> </span></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Capital expenditures for:</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Property and equipment</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5951">132</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5952">363</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Intangible assets</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5953">5</ix:nonFraction>)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D230101_230630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5954">-</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">Proceeds from sale of property and equipment</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5955">27</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D230101_230630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5956">-</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Net cash used in investing activities</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5957">110</ix:nonFraction>) </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D230101_230630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5958">363</ix:nonFraction>) </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Proceeds from issuance of common stock - options</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5959">390</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5960">81</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5961">9,393</ix:nonFraction>)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D230101_230630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5962">-</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Payment of dividends</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5963">2,170</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5964">2,140</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Net cash used in financing activities</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5965">11,173</ix:nonFraction>)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D230101_230630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5966">2,059</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Effect of exchange rate changes on cash</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5967">404</ix:nonFraction>)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5968">161</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Net increase in cash and cash equivalents</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5969">3,649</ix:nonFraction>) </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5970">9,567</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Cash at beginning of period</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5971">92,868</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E22" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5972">75,052</ix:nonFraction></p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Cash at end of period</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5973">89,219</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5974">84,619</ix:nonFraction> </p>
</td></tr>
<tr style="height:13.5pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td colspan="2" valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Cash paid during the period for income taxes</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5975">2,791</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5976">2,546</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Cash paid during the period for interest</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="D240101_240630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5977">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="D230101_230630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5978">-</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;margin-left:10.1pt">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">3</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a8"></a><p style="font:10pt CG Times;margin:0"></p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.75pt"><td colspan="12" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="12" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="12" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023</span></p>
</td></tr>
<tr style="height:12.75pt"><td colspan="12" valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(In thousands - unaudited)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Accumulated</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Additional</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Other</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Common Stock</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Paid-in</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Comprehensive</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Retained</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Stockholders'</p>
</td></tr>
<tr style="height:12.75pt"><td valign="bottom" style="padding-right:5.75pt"/><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Shares</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Amount</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Capital</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Income (Loss)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Earnings</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Equity</p>
</td></tr>
<tr style="height:18.75pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Balance at December 31, 2023</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5979">3,630</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5980">36</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5981">593</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5982">10,658</ix:nonFraction>)</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5983">138,341</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5984">128,313</ix:nonFraction></p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5985">2</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5986">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5987">96</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5988">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5989">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5990">96</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Stock option compensation expense</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5991">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5992">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5993">79</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5994">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5995">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5996">79</ix:nonFraction></p>
</td></tr>
<tr style="height:12.75pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">Common stock purchased and retired</span></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5997">43</ix:nonFraction>)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5998">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5999">769</ix:nonFraction>)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6000">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6001">2,221</ix:nonFraction>)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6002">2,990</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Foreign currency translation adjustment</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6003">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6004">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6005">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6006">631</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6007">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6008">631</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Common stock dividends</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6009">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6010">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6011">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6012">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6013">1,081</ix:nonFraction>)</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6014">1,081</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.75pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Net income</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6015">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6016">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6017">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6018">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6019">3,956</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6020">3,956</ix:nonFraction></p>
</td></tr>
<tr style="height:18.75pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Balance at March 31, 2024</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6021">3,588</ix:nonFraction></p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6022">36</ix:nonFraction></p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6023">-</ix:nonFraction></p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6024">11,289</ix:nonFraction>)</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6025">138,995</ix:nonFraction></p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6026">127,742</ix:nonFraction></p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6027">6</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6028">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6029">294</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6030">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6031">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6032">294</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Stock option compensation expense</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6033">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6034">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6035">52</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6036">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6037">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6038">52</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">Common stock purchased and retired</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6039">95</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6040">1</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6041">346</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6042">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6043">6,056</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6044">6,403</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Foreign currency translation adjustment</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6045">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6046">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6047">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6048">33</ix:nonFraction>) </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6049">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6050">33</ix:nonFraction>) </p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Common stock dividends</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6051">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6052">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6053">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6054">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6055">1,052</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6056">1,052</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Net income</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6057">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6058">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6059">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6060">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6061">3,453</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6062">3,453</ix:nonFraction> </p>
</td></tr>
<tr style="height:18.75pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Balance at June 30, 2024</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6063">3,499</ix:nonFraction> </p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6064">35</ix:nonFraction> </p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6065">0</ix:nonFraction>) </p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6066">11,322</ix:nonFraction>)</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6067">135,339</ix:nonFraction> </p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6068">124,052</ix:nonFraction> </p>
</td></tr>
<tr style="height:25.5pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt CG Times;margin:0">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:18.7pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Balance at December 31, 2022</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E22_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6069">3,628</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E22_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6070">36</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E22_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6071">251</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E22_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6072">12,039</ix:nonFraction>)</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E22_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6073">126,006</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E22" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6074">114,254</ix:nonFraction></p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-6075">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6076">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6077">21</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6078">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6079">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6080">21</ix:nonFraction></p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Stock option compensation expense</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6081">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6082">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6083">50</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6084">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6085">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6086">50</ix:nonFraction></p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Foreign currency translation adjustment</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6087">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6088">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6089">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6090">549</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6091">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6092">549</ix:nonFraction></p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Common stock dividends</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6093">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6094">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6095">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6096">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6097">1,070</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6098">1,070</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Net income</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6099">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6100">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6101">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6102">-</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6103">4,214</ix:nonFraction></p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6104">4,214</ix:nonFraction></p>
</td></tr>
<tr style="height:18.75pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Balance at March 31, 2023</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E23Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6105">3,628</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6106">36</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6107">322</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6108">11,491</ix:nonFraction>)</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6109">129,150</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6110">118,018</ix:nonFraction></p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6111">1</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6112">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6113">60</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6114">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6115">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6116">60</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Stock option compensation expense</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6117">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6118">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6119">50</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6120">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6121">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6122">50</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Foreign currency translation adjustment</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6123">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6124">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6125">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6126">504</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6127">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6128">504</ix:nonFraction> </p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Common stock dividends</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6129">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6130">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6131">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6132">-</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6133">1,071</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6134">1,071</ix:nonFraction>)</p>
</td></tr>
<tr style="height:12.95pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Net income</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6135">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6136">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6137">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6138">-</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6139">4,200</ix:nonFraction> </p>
</td><td valign="bottom" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6140">4,200</ix:nonFraction> </p>
</td></tr>
<tr style="height:18.75pt"><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> Balance at June 30, 2023</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E23Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6141">3,629</ix:nonFraction> </p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6142">36</ix:nonFraction> </p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6143">432</ix:nonFraction> </p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6144">10,986</ix:nonFraction>)</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6145">132,279</ix:nonFraction> </p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6146">121,761</ix:nonFraction> </p>
</td></tr>
<tr style="height:18.75pt"><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt CG Times;margin:0">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:18.75pt"><td valign="bottom" style="padding-right:5.75pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">4</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a9"></a><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(unaudited)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2897"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2023. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
</ix:nonNumeric><p style="font:10pt CG Times;margin:0">&#160;</p>
 <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2900"><p style="font:10pt Times New Roman;margin:0;color:#000000">(2) Recent Accounting Standards. </p>
 <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2902"><p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.</p>
</ix:nonNumeric></ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2906"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">(3) Inventories at June 30, 2024 and December 31, 2023 consisted of the following:</p>
<ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2908"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td valign="top" style="width:172.9pt"/><td valign="top" style="width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> June 30, 2024</p>
</td><td valign="top" style="width:13.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2023</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td valign="top" style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6147">1,334</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6148">1,685</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:172.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td valign="top" style="width:16.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:130.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6149">1,435</ix:nonFraction></p>
</td><td valign="top" style="width:13.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:16.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:122.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6150">1,503</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td valign="top" style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6151">6,289</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6152">6,394</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:172.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td valign="top" style="width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6153">9,058</ix:nonFraction></p>
</td><td valign="top" style="width:13.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td valign="top" style="width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6154">9,582</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric></ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2975"><p style="font:10pt Times New Roman;margin:0">(4) Stock-Based Compensation. At June 30, 2024, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2024 and 2023, the Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6155">52</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6156">50</ix:nonFraction>, respectively, in stock based compensation cost. &#160;In the six months ended June 30, 2024 and 2023, the Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6157">131</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6158">100</ix:nonFraction>, respectively, in stock based compensation expense.</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:ProductWarrantyDisclosureTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2979"><p style="font:10pt Times New Roman;margin:0"> (5) Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, <ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="E23" decimals="INF" unitRef="USD" format="ixt:fixed-zero" id="ixv-6159"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="E24Q2" decimals="INF" unitRef="USD" format="ixt:fixed-zero" id="ixv-6160">no</ix:nonFraction></ix:nonFraction> warranty reserve was made at December 31, 2023 or June 30, 2024. </p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2984"><p style="font:10pt Times New Roman;margin:0">(6) Global 2Q 2024 revenues (USD) by product category:</p>
<ix:nonNumeric name="fil:ScheduleOfRevenuesByProductCategoryTextBlock" contextRef="D240101_240630" escape="true" id="ixv-2986"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td valign="top" style="width:180pt"/><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td valign="top" style="width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-Obstetrics_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6161">852</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-Obstetrics_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6162">167</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-Obstetrics" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6163">1,019</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6164">2,410</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6165">3,042</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6166">5,452</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-Neonatal_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6167">1,231</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-Neonatal_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6168">315</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-Neonatal" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6169">1,546</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6170">1,338</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6171">1,045</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6172">2,383</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6173">5,831</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6174">4,569</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6175">10,400</ix:nonFraction></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 1H 2024 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td valign="top" style="width:180pt"/><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td valign="top" style="width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-Obstetrics_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6176">1,656</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-Obstetrics_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6177">388</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-Obstetrics" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6178">2,044</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6179">4,762</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6180">6,150</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6181">10,912</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-Neonatal_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6182">2,477</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-Neonatal_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6183">711</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-Neonatal" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6184">3,188</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6185">3,127</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6186">2,469</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6187">5,596</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6188">12,022</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6189">9,718</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6190">21,740</ix:nonFraction></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</ix:nonNumeric></ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">5</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/> <ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="D240101_240630" escape="true" id="ixv-3250"><p style="font:10pt Times New Roman;margin:0">(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#174; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $<ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6191">21,000</ix:nonFraction> purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of expenses over the <ix:nonFraction name="fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem" contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc" decimals="INF" unitRef="Pure" scale="0" format="ixt:num-dot-decimal" id="ixv-6192">4.75</ix:nonFraction> year remaining life of the CSI distribution agreement with Femcare Ltd which ended in October 2023.</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<span style="font-family:Times New Roman;color:#000000"> </span><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="D240101_240630" escape="true" id="ixv-3254"><p style="font:10pt Times New Roman;margin:0">(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="D240101_240630" escape="true" id="ixv-3257"><p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td valign="top" style="width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><i>(in thousands)</i></p>
</td><td colspan="3" valign="top" style="width:151.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td valign="top" style="width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="top" style="width:151.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six months ended</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top" style="width:151.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td valign="top" style="width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="top" style="width:151.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:159.5pt;padding-right:5.75pt"/><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td valign="top" style="width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td valign="top" style="width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td valign="top" style="width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td valign="top" style="width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6193">3,453</ix:nonFraction></p>
</td><td valign="top" style="width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6194">4,200</ix:nonFraction></p>
</td><td valign="top" style="width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6195">7,409</ix:nonFraction></p>
</td><td valign="top" style="width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D230101_230630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6196">8,414</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td valign="top" style="width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td valign="top" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:70.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6197">3,532</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y23Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6198">3,628</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D240101_240630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6199">3,579</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D230101_230630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6200">3,628</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y24Q2" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-6201">-</ix:nonFraction></p>
</td><td valign="top" style="width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y23Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6202">11</ix:nonFraction></p>
</td><td valign="top" style="width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D240101_240630" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-6203">-</ix:nonFraction></p>
</td><td valign="top" style="width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D230101_230630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6204">10</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6205">3,532</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y23Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6206">3,639</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D240101_240630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6207">3,579</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D230101_230630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6208">3,638</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.65pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6209">0.98</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y23Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6210">1.16</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D240101_240630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6211">2.07</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D230101_230630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6212">2.32</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:159.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6213">0.98</ix:nonFraction></p>
</td><td valign="top" style="width:10.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y23Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6214">1.15</ix:nonFraction></p>
</td><td valign="top" style="width:11.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D240101_240630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6215">2.07</ix:nonFraction></p>
</td><td valign="top" style="width:10.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:70.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D230101_230630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6216">2.31</ix:nonFraction></p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="D240101_240630" escape="true" id="ixv-3468"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements<b>.  </b>After June 30, 2024 through August 8, 2024, the Company made additional repurchases of <ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="D240701_240808" decimals="INF" unitRef="Shares" scale="0" format="ixt:num-dot-decimal" id="ixv-6217">21,785</ix:nonFraction> shares of its stock in the open market for $<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D240701_240808" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6218">1,441</ix:nonFraction>, at an average price of $<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" contextRef="D240701_240808" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6219">66.15</ix:nonFraction> per share.</p>
</ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">6</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a10"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">General</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2023 provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. &#160;Because of the relatively short span of time, results for any given three- or six-month period in comparison with a previous three- or six-month period may not be indicative of comparative results for the year as a whole. Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&#160;or GBP = UK Pound Sterling; CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Analysis of Results of Operations</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>a) &#160;Overview&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Income statement results in second calendar quarter (2Q) and first half (1H) 2024 compared to the same periods of 2023 were as follows:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:231.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2023</span></p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">change</span></p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2023</span></p>
</td><td valign="top" style="width:76.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:231.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Net Sales</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 10,400</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 12,866</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(19.2%)</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 21,740</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 25,386</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(14.4%)</p>
</td></tr>
<tr><td valign="top" style="width:231.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,253</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,739</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(19.2%)</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">13,018</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">15,581</p>
</td><td valign="top" style="width:76.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(16.4%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:231.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,438</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,425</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(22.3%)</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,321</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,864</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(17.4%)</p>
</td></tr>
<tr><td valign="top" style="width:231.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Income Before Tax</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,211</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,172</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(18.6%)</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,010</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,291</p>
</td><td valign="top" style="width:76.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(12.5%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:231.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Net Income (US GAAP) </p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,453</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,200</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(17.8%)</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,409</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,414</p>
</td><td valign="top" style="background-color:#CCEEFF;width:76.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(11.9%)</p>
</td></tr>
<tr><td valign="top" style="width:231.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per Diluted Share </p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 0.978</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 1.154</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(15.3%)</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 2.070</p>
</td><td valign="top" style="width:76.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 2.313</p>
</td><td valign="top" style="width:76.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(10.5%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated 2Q 2024 revenues were $2,466 (19.2%) lower than in 2Q 2023, with 1H 2024 revenues $3,646 (14.4%) lower than in 1H 2023. &#160;The decline in sales in three categories explain more than the total consolidated sales decline. &#160;WW in the table below = &#8220;worldwide&#8221;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:329pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt"><span style="border-bottom:1px solid #000000">Revenue Category</span></p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">Portion of 2Q Lower Total <span style="border-bottom:1px solid #000000">UTMD Sales</span></p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">Portion of 1H Lower Total <span style="border-bottom:1px solid #000000">UTMD Sales</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:329pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">WW PendoTECH OEM</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">70%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">76%</p>
</td></tr>
<tr><td valign="top" style="width:329pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">China BPM Distributor</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">21%</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">12%</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:329pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">WW Filshie Clip System</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">16%</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">25%</span></p>
</td></tr>
<tr><td valign="top" style="width:329pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Total:</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">107%</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">113%</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In other words, aggregated consolidated sales in all other sales categories were higher when comparing 2024 to 2023 in both periods. &#160;Despite the significantly lower sales, UTMD achieved profit margins in all income categories similar to those of the prior year&#8217;s same periods:</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:328.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt">&#160;</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">2Q 2024 </p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">(Apr &#8211;&#160;Jun)</span></p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center">2Q 2023</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">(Apr &#8211;&#160;Jun)</span></p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">1H 2024 </p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">(Jan &#8211;&#160;Jun)</span></p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center">1H 2023</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">(Jan &#8211;&#160;Jun)</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:328.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Gross Profit Margin (Gross Profit/ sales):</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">60.1%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">60.1%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">59.9%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">61.4%</p>
</td></tr>
<tr><td valign="top" style="width:328.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Operating Income Margin (Operating Income/ sales):</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">33.1%</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">34.4%</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">33.7%</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">34.9%</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:328.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Income Before Tax Margin (Income B4 Tax/ sales):</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">40.5%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">40.2%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">41.4%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">40.5%</p>
</td></tr>
<tr><td valign="top" style="width:328.95pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Net Income Margin (Net Income/ sales):</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">33.2%</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">32.6%</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">34.1%</p>
</td><td valign="top" style="width:90.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">33.1%</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The percentage decline in 2Q consolidated revenues was greater than for 1H primarily because the period-to-period decline in UTMD sales to its previously major biopharmaceutical OEM customer increased from $1,046 in 1Q 2024 to $1,732 in 2Q 2024. UTMD now expects a similar magnitude of decline in the last two quarters of the year as occurred in 2Q 2024, resulting in $6 million lower sales to this OEM customer for the 2024 year as a whole compared to 2023. &#160;UTMD was able to achieve the same GP margin in 2Q 2024 as in 2Q 2023 despite 19% lower sales after making timely reductions in manufacturing expenses. The Company believes that the reductions were made without sacrificing critical resources needed for longer term growth. &#160;Operating Income declined more than Gross Profit due to $689 higher 1H 2024 U.S. litigation costs which are included in Operating Expense per US GAAP. Higher non-operating income brought the decline in Income Before Tax to be in line with the decline in sales. &#160;A lower estimated income tax provision rate mitigated the decline in Net Income, and share repurchases during 1H 2024 helped further reduce the decline in Earnings Per Share relative to the sales decline.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s June 30, 2024 Balance Sheet continued strong, with no debt. Ending Cash and Investments were $89.2 million on June 30, 2024 compared to $92.9 million on December 31, 2023. &#160;The June 30, 2024 cash balance resulted after paying $2.2 million in cash dividends to stockholders, repurchasing $9.4 million of its common stock, increasing non-cash working capital by $0.5 million (including reducing current liabilities by $0.8 million) and making $0.1 million in capital expenditures during 1H 2024. &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">7</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0">Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 2Q 2024 compared to the end of calendar year 2023 and the end of 2Q 2023 were</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:118.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">6-30-24</span></p>
</td><td valign="top" style="width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">12-31-23</span></p>
</td><td valign="top" style="width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td><td valign="top" style="width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">6-30-23</span></p>
</td><td valign="top" style="width:114.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:118.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.26371</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.27386</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(0.8%)</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.27084</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(0.6%)</p>
</td></tr>
<tr><td valign="top" style="width:118.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.07109</p>
</td><td valign="top" style="width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.10593</p>
</td><td valign="top" style="width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(3.2%)</p>
</td><td valign="top" style="width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.09178</p>
</td><td valign="top" style="width:114.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(1.9%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:118.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.66742</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.68248</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(2.2%)</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.66614</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.2%</p>
</td></tr>
<tr><td valign="top" style="width:118.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.73068</p>
</td><td valign="top" style="width:114.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.75733</p>
</td><td valign="top" style="width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(3.5%)</p>
</td><td valign="top" style="width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.75547</p>
</td><td valign="top" style="width:114.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(3.3%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>b) &#160;Revenues&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. In the U.S., Ireland, UK, France, Canada, Australia and New Zealand, UTMD accepts orders directly from and ships directly to end user medical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale. UTMD&#8217;s T&amp;C of Sale to end user facilities are substantially the same in the U.S. and OUS. UTMD also has standard T&amp;C of Sale for OEM customers, other medical device and non-medical device customers for components manufactured by UTMD, which are substantially the same, except that prices are generally quoted prior to acceptance of each order.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD may have separate discounted pricing agreements with a specific clinical facility, or group of affiliated facilities or large OEM customers based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities or OEM customers, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements based on volume of purchases disclosure is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><span style="border-bottom:1px solid #000000">2Q 2024 Sales</span></p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated 2Q 2024 UTMD worldwide (WW) sales in USD terms were $2,466 (19.2%) lower than in 2Q 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consistent with the projection in UTMD&#8217;s SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD&#8217;s previously largest OEM customer, PendoTECH, invoiced by both the U.S. and Ireland, were $1,732 (77.3%) lower in 2Q 2024 compared to 2Q 2023. (There were no Ireland sales to PendoTech in 2Q 2024 compared to $608 in 2Q 2023.) &#160;New orders received from PendoTECH scheduled for the 2H 2024 have been minimal, resulting in a current backlog for WW PendoTECH shipments during the remainder of 2024 of approximately $450. As WW PendoTECH shipments in 2H 2023 were $3,798, UTMD expects that, without any new orders, 3Q and 4Q 2024 shipments, consistent with 2Q 2024, will also each be about $1.7 million lower as in the same periods in 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The timing of shipments to OUS distributors can cause significant fluctuations in quarterly comparisons since distributors order larger quantities at a time in order to minimize transit and other logistical costs. &#160;The second major revenue decline category, which was also as projected in UTMD&#8217;s 2024 SEC 10-K Report, was due to shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD&#8217;s largest BPM medical device distributor located in China. This customer places annual fixed orders with UTMD. &#160;In 2Q 2024, sales were $502 (39.3%) lower due to an extra shipment in 2Q 2023 compared to 2Q 2024. &#160;Unlike 2Q 2024, 3Q 2024 shipments will not be lower than 3Q 2023 to this distributor, but 4Q 2024 shipments are scheduled to be $1.2 million lower.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">With a high level of uncertainty, UTMD projected that it would be able to maintain Filshie Clip System device (Filshie) sales in 2024 similar to 2023. &#160;Filshie sales were the third major category responsible for lower total sales. &#160;WW consolidated Filshie sales in 2Q 2024 were $405 (12.8%) lower than in 2Q 2023. &#160;Domestic Filshie sales were $165 (13.9%) lower, OUS direct sales were $149 (10.0%) lower and OUS distributor sales were $91 (19.1%) lower.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In sum, the 2Q 2024 decline in sales from the three categories above compared to 2Q 2023 was $2,639, which is obviously greater than the aggregate $2,466 decline in total consolidated sales.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In 2Q 2024 compared to 2Q 2023, outside the U.S. (OUS) sales were $1,280 (21.9%) lower and U.S. domestic sales were $1,186 (16.9%) lower.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The portion of OUS sales invoiced in foreign currencies in USD terms were 35% of total WW consolidated 2Q 2024 sales compared to 33% in 2Q 2023. The net impact of changes in period-to-period foreign currency exchange (FX) rates was negligible. The average USD FX rates reduced 2Q 2024 total consolidated sales $23 (0.2%) for sales invoiced in foreign currencies. Actually, a stronger GBP by itself added $6. The EUR, CAD and AUD were weaker. &#160;FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 2Q 2024 and 2Q 2023 for revenue purposes follow: &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2023</span></p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.2615</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.2531</p>
</td><td valign="top" style="background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">+0.7%</p>
</td></tr>
<tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.0752</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.0845</p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(0.9%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.6594</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.6700</p>
</td><td valign="top" style="background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(1.6%)</p>
</td></tr>
<tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.7308</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.7449</p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(1.9%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The $23 weighted average unfavorable impact on 2Q 2024 foreign currency OUS sales was 0.6%. &#160;In constant currency terms, foreign currency sales in 2Q 2024 were 21.5% lower than in 2Q 2023. &#8220;Constant currency&#8221; sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Total OUS sales in 2Q 2024 were $4,569 compared to $5,849 in 2Q 2023. OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &#160;Export sales from the U.S. to OUS distributors are invoiced in USD. &#160;Direct to end-user OUS 2Q 2024 sales in USD terms (including the impact of FX rate differences) were 8.3% higher in Ireland with the EUR FX rate down about 0.9%, 12.3% lower in Canada with the CAD FX rate down 1.9%, 13.1% higher in the UK with the GBP FX rate up 0.7%, 9.6% lower in Australia/New Zealand with the AUD FX rate down 1.6%, and 25.5% lower in France with the EUR FX rate down only 0.9%. USD-denominated sales to OUS distributors were 30.7% lower in 2Q 2024 than in 2Q 2023 because Ireland sales to PendoTECH as well as sales to UTMD&#8217;s BPM device distributor in China are in this category. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic U.S. sales in 2Q 2024 were $5,831 compared to $7,017 in 2Q 2023. &#160;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct non-Filshie device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;domestic Filshie device sales&#8221;. UTMD separates domestic Filshie device sales from other medical device sales direct to medical facilities because UTMD is simply a distributor for Femcare in the U.S. &#160;Direct non-Filshie device sales, representing 63% of total domestic sales, were about the same, just $8 (0.2%) lower in 2Q 2024 than in 2Q 2023. Domestic OEM sales, representing 20% of total domestic sales, in total were $1,013 (47.0%) lower. In this category, U.S. PendoTECH sales were $1,124 lower. &#160;Domestic Filshie device sales, representing 17% of total domestic sales, were $165 (13.9%) lower in 2Q 2024 compared to 2Q 2023.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">8</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><span style="border-bottom:1px solid #000000">1H 2024 Sales</span></p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated 1H 2024 UTMD WW sales in USD terms were $3,646 (14.4%) lower than in 1H 2023. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consistent with the projection in UTMD&#8217;s SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD&#8217;s previously largest OEM customer, PendoTECH, invoiced by both the U.S. and Ireland, were $2,788 (57.5%) lower in 1H 2024 compared to 1H 2023. Ireland sales alone to PendoTech in 1H 2024 were $919 lower than in 1H 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The second major revenue decline category, which was also as projected in UTMD&#8217;s 2024 SEC 10-K Report, was due to shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD&#8217;s largest BPM medical device distributor located in China. In 1H 2024, sales were $415 (20.7%) lower due to an extra shipment in 2Q 2023 compared to 2Q 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">With a high level of uncertainty, UTMD projected maintaining Filshie Clip System device (Filshie) sales in 2024 similar to 2023. &#160;This was the third major category responsible for lower 1H sales. &#160;WW consolidated Filshie sales in 1H 2024 were $918 (14.2%) lower than in 1H 2023. &#160;Domestic Filshie sales were $362 (14.8%) lower, OUS direct sales were $266 (8.8%) lower and OUS distributor sales were $290 (29.0%) lower.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In sum, the 1H 2024 decline in sales from the three categories above compared to 1H 2023 was $4,111, which is obviously greater than the $3,646 decline in total consolidated sales. In 1H 2024 compared to 1H 2023, OUS sales were $1,466 (13.1%) lower and U.S. domestic sales were $2,180 (15.3%) lower. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Total OUS sales in 1H 2024 were $9,718 compared to $11,184 in 1H 2023. The portion of OUS sales invoiced in foreign currencies in USD terms were 33% of total WW consolidated 1H 2024 sales compared to 31% in 1H 2023 because Ireland sales to PendoTECH were invoiced in USD. The net impact of changes in period-to-period foreign currency exchange (FX) rates was negligible. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1H 2024 and 1H 2023 for revenue purposes follow: &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1H 2023</span></p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.2646</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.2329</p>
</td><td valign="top" style="background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">+2.6%</p>
</td></tr>
<tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.0787</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.0819</p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(0.3%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.6586</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.6774</p>
</td><td valign="top" style="background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(2.8%)</p>
</td></tr>
<tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.7362</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.7419</p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(0.8%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The weighted-average FX rate positive impact on 1H 2024 foreign currency OUS sales was 0.2%. In constant currency terms, foreign currency sales in 1H 2024 were 8.3% lower than in 1H 2023. &#160;In constant currency terms, 1H 2024 total OUS sales were 13.3% lower than in 1H 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Direct to end-user OUS 1H 2024 sales in USD terms (including the impact of FX rate differences) were 20% higher in Ireland with the EUR FX rate about the same, 10% lower in Canada with the CAD FX rate down 1%, 8% higher in the UK with the GBP FX rate 3% higher, 17% lower in Australia/New Zealand with the AUD FX rate down 3%, and 20% lower in France with the EUR FX rate about the same as in 1H 2023. USD-denominated sales to OUS distributors (excluding PendoTECH) were 7% lower in 1H 2024 than in 1H 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic U.S. sales in 1H 2024 were $12,023 compared to $14,202 in 1H 2023. Direct non-Filshie device sales, representing 60% of total domestic sales, were $114 (1.6%) lower in 1H 2024 than in 1H 2023. Domestic OEM sales, representing 23% of total domestic sales, were $1,704 (38.2%) lower. In this category, since U.S. PendoTECH sales were $1,860 lower, other U.S. OEM sales were obviously $156 higher. Domestic Filshie device sales, representing 17% of total domestic sales, were $362 (14.8%) lower in 1H 2024 compared to 1H 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table provides USD-denominated sales amounts divided into general product categories for total revenues and the subset of OUS revenues:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Global revenues by product category</span>:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2023</span></p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2023</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1,019</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1,075</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,044</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,090</p>
</td></tr>
<tr><td valign="top" style="width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,452</p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,917</p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,912</p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,510</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,546</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,396</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,188</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,158</p>
</td></tr>
<tr><td valign="top" style="width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2,383</span></p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">4,478</span></p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">5,596</span></p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">8,628</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 10,400</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 12,866</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 21,740</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 25,386</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">OUS revenues by product category</span>:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2023</span></p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2023</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 167</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 221</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 388</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 430</p>
</td></tr>
<tr><td valign="top" style="width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,042</p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,232</p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,150</p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,304</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">315</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">252</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">711</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">630</p>
</td></tr>
<tr><td valign="top" style="width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1,045</span></p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2,144</span></p>
</td><td valign="top" style="width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2,469</span></p>
</td><td valign="top" style="width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3,820</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 4,569</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 5,849</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 9,718</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 11,184</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:37.8pt"></kbd>* includes assemblies and molded components sold to OEM customers.&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In view of lack of orders from its previous largest OEM customer and ongoing weakness in Filshie device sales, UTMD now projects 2024 sales for the year as a whole are likely to be 20-22% lower than in 2023.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">9</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>c) &#160;Gross Profit &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Gross Profit results from subtracting the cost of goods sold (CGS), comprised of costs of production, manufacturing engineering, depreciation of equipment, maintenance and repairs, quality assurance including regulatory compliance, and purchasing materials including freight for receiving materials from suppliers, from revenues. CGS is divided into three categories: direct labor, raw materials and manufacturing overhead (MOH). &#160;Direct labor and raw materials are predominantly variable costs, i.e. vary directly with revenues. &#160;MOH contains predominantly fixed costs relative to the Company&#8217;s infrastructure, for example, supervision and engineering personnel.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s 2Q 2024 Gross Profit was $1,486 (19.2%) lower than in 2Q 2023, the same decline as in sales, due to being able to achieve the same Gross Profit Margin (GP divided by sales, GPM). Gross Profit in 1H 2024 was $2,563 (16.4%) lower than in 1H 2023 with sales 14.4% lower, as UTMD&#8217;s 1Q 2024 GPM was diluted from manufacturing overhead expenses which had not yet been reduced in proportion to sales. The 1H 2024 GPM was 59.9% compared to 61.4% in 1H 2023. &#160;UTMD&#8217;s 2024 GPMs were consistent with UTMD&#8217;s long-term profitability goals.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">With lower sales and consequent lower absorption of fixed MOH costs, a higher than expected 2Q 2024 average GPM was achieved through several means; 1) a favorable product sales mix, i.e. lower sales to UTMD&#8217;s China distributor at UTMD&#8217;s lowest GPM, 2) a direct labor productivity improvement as the least experienced production workers were furloughed, 3) reduction of some production supervision and management, 4) relief in marginal costs of some raw materials, 5) substantially lower incoming freight costs from raw material vendors, and 6) a reduction in intercompany finished goods inventory which freed up reserved gross profit. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>d) &#160;Operating Income &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Operating Income results from subtracting Operating Expenses from Gross Profit. &#160;Operating Expenses are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Operating Income in 2Q 2024 of $3,438 was $987 (22.3%) lower compared to 2Q 2023 Operating Income of $4,425. &#160;The lower Operating Income was the result of $1,486 lower Gross Profit offset in part by $499 lower Operating Expense, as explained below. UTMD&#8217;s 2Q 2024 Operating Income Margin (Operating Income as a percentage of sales) remained a healthy 33.1%.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Operating Income in 1H 2024 was $7,321 compared to $8,864 in 1H 2023, a decrease of $1,542 (17.4%), but still achieving a healthy 1H 2024 Operating Income Margin of 33.7%. &#160;The lower Operating Income was the result of $2,563 lower Gross Profit offset in part by $1,020 lower Operating Expense, as explained below.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table summarizes Operating Expenses in 2Q and 1H 2024 compared to the same periods in 2023 by Operating Expense (OE) category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:351.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">OE Category</span></p>
</td><td valign="top" style="width:85.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:85.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">% of sales</span></p>
</td><td valign="top" style="width:85.6pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2023</span></p>
</td><td valign="top" style="width:85.6pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">% of sales</span></p>
</td><td valign="top" style="width:100.5pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:100.55pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">% of sales</span></p>
</td><td valign="top" style="width:100.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2023</span></p>
</td><td valign="top" style="width:100.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">% of sales</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:351.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">S&amp;M:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:85.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;546</p>
</td><td valign="top" style="background-color:#CCEEFF;width:85.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.3</p>
</td><td valign="top" style="background-color:#CCEEFF;width:85.6pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;405</p>
</td><td valign="top" style="background-color:#CCEEFF;width:85.6pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.2</p>
</td><td valign="top" style="background-color:#CCEEFF;width:100.5pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;958</p>
</td><td valign="top" style="background-color:#CCEEFF;width:100.55pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4.4</p>
</td><td valign="top" style="background-color:#CCEEFF;width:100.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;792</p>
</td><td valign="top" style="background-color:#CCEEFF;width:100.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.1</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:351.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">G&amp;A:</p>
</td><td valign="top" style="width:85.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,014</p>
</td><td valign="top" style="width:85.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">19.4</p>
</td><td valign="top" style="width:85.6pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,775</p>
</td><td valign="top" style="width:85.6pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">21.6</p>
</td><td valign="top" style="width:100.5pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,219</p>
</td><td valign="top" style="width:100.55pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">19.4</p>
</td><td valign="top" style="width:100.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,648</p>
</td><td valign="top" style="width:100.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">22.3</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:351.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">R&amp;D:</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:85.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">255</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:85.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2.4</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:85.6pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">133</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:85.6pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1.0</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:100.5pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">520</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:100.55pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2.4</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:100.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">277</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:100.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1.1</span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:351.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Total OE:</p>
</td><td valign="top" style="width:85.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,815</p>
</td><td valign="top" style="width:85.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">27.1</p>
</td><td valign="top" style="width:85.6pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 3,313</p>
</td><td valign="top" style="width:85.6pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">25.8</p>
</td><td valign="top" style="width:100.5pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 5,697</p>
</td><td valign="top" style="width:100.55pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">26.2</p>
</td><td valign="top" style="width:100.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 6,717</p>
</td><td valign="top" style="width:100.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">26.5</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">S&amp;M Operating Expenses were $141 and $165 higher in 2Q 2024 and 1H 2024 compared to the same periods in 2023 respectively. &#160;UTMD in the U.S. is self-insured for its employee health plan. &#160;One employee&#8217;s 2Q medical claim that did not occur in the prior year explains about $100 of the difference in both periods. An earlier timing of trade shows in 2Q than in the prior year together with higher travel expenses explains about another $20 of the 2Q and 1H 2024 differences to same periods in 2023. The remaining differences are primarily due to higher salaries for existing S&amp;M employees in 2024 compared to 2023 worldwide. The impact of differences in FX rates on foreign subsidiary S&amp;M expenses was insignificant (see below). &#160;Because of lower sales in addition to the higher expenses, S&amp;M expenses as a percentage of sales increased to 5.3% in 2Q 2024 from 3.2% in 2Q 2023, and to 4.4% of sales in 1H 2024 from 3.1% in 1H 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">G&amp;A expenses dominate UTMD&#8217;s Operating Expenses, largely because of non-cash expenses from the amortization of Identifiable Intangible Assets (IIA) associated with the Filshie Clip System and the expenses of current product liability litigation in the U.S. &#160;A segmentation of USD-denominated G&amp;A expenses follows:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">G&amp;A OE Category</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">% of sales</span></p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2023</span></p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">% of sales</span></p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">% of sales</span></p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2023</span></p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">% of sales</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">IIA Amort&#8211; UK:</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;501</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4.8</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;498</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.9</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;1,005</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4.6</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;981</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.9</p>
</td></tr>
<tr><td valign="top" style="width:221.55pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">IIA Amort&#8211; CSI:</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,105</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">8.6</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,210</p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">8.7</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">Other&#8211; UK:</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">173</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">163</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">360</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">327</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:221.55pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">U.S. Litigation:</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">635</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">6.1</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">280</span></p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.2</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,378</span></p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">6.3</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">689</span></p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.7</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">Other&#8211; US:</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">557</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.4</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">588</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4.6</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,158</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.3</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,150</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4.5</p>
</td></tr>
<tr><td valign="top" style="width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">IRE:</p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">92</p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">69</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">186</p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">153</p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">AUS:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">24</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">35</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">66</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">69</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">CAN:</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">32</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">37</span></p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">66</span></p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">69</span></p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Total G&amp;A OE:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,014</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">19.4</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,775</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">21.6</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 4,219</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">19.4</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 5,648</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">22.2</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated G&amp;A Operating Expenses in 2Q 2024 were $761 lower, and in 1H 2024 were $1,429 lower than in the same periods in 2023. &#160;The amortization of IIA associated with UTMD&#8217;s purchase of CooperSurgical Inc&#8217;s exclusive U.S. distribution and use of intellectual property rights in 2019 was fully amortized in late 2023. &#160;In the 1H of 2024, this reduced G&amp;A Operating Expense by $1,105 per calendar quarter compared to 2023. &#160;Offsetting that significant G&amp;A expense reduction was an increase in U.S. litigation expenses related to the Filshie Clip System of $355 in 2Q 2024 compared to 2Q 2023, and $689 in 1H 2024 compared to 1H 2023. &#160;The remaining IIA amortization expense in the UK resulted from the 2011 acquisition of Femcare. This expense only varied as a result of the change in the GBP FX rate, as the amortization expense in GBP was the same in both periods. All other G&amp;A expenses in the aggregate were similar in both periods.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The differences in period-to-period R&amp;D expenses were due to extensive outside material validation studies in 2024 required by biopharmaceutical industry manufacturers for devices used in their manufacturing processes. Since all R&amp;D in 2024 was carried out in the U.S., there was no FX rate impact.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">10</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0">The impact of differing FX rates in 2024 and 2023 on Operating Expenses expressed in USD was negligible. The EUR, AUD and CAD were all slightly weaker, but an average stronger GBP helped increase foreign currency Operating Expense when converted to USD by a net $2 in 2Q 2024 and $30 in 1H 2024. The following table summarizes &#8220;constant currency&#8221; Operating Expense in 2Q and 1H 2024 compared to the same periods in 2023 by Operating Expense category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">OE Category</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024 const FX</span></p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2023</span></p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024 const FX</span></p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2023</span></p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">S&amp;M:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;547</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;405</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;958</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;792</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">G&amp;A:</p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,011</p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,775</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,189</p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,648</p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">R&amp;D:</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">255</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">133</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">520</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">277</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:221.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Total OE:</p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,813</p>
</td><td valign="top" style="width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 3,313</p>
</td><td valign="top" style="width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 5,667</p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 6,717</p>
</td><td valign="top" style="width:63.4pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>e) &#160;Non-operating expense/ Non-operating income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Non-operating expense includes bank fees and expenses from losses, if applicable, from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. &#160;Non-operating income includes 1) income from rent of underutilized property, 2) investment income (interest on cash balances), 3) royalties received from licensing the Company&#8217;s technology, and 4) income from gains, if applicable, from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. Non-operating income or expense can also include gains or losses from the disposition of assets from time to time. Starting in 2024 for UTMD, there is an additional excise tax included in non-operating expenses: a stock repurchase excise tax included in the so-called &#8220;Inflation Reduction Act of 2022&#8221;. &#160;Although the new 1% tax on the aggregate fair market value of share repurchases made in 2023 applies, UTMD did not repurchase shares in 2023. After the U.S. Treasury and IRS announced regulations governing the stock repurchase excise tax in 2Q 2024, UTMD began reporting the stock repurchase excise tax in its 2Q 2024 non-operating expenses based on $9,393 in share repurchases made during 1H 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Net non-operating income is non-operating income minus non-operating expense during a particular time period. </p>
<p style="font:10pt Times New Roman;margin:0">Net non-operating income in 2Q 2024 was $773 compared to $747 in 2Q 2023. Net non-operating income in 1H 2024 was $1,688 compared to $1,427 in 1H 2023. Non-operating income in 2Q 2024 was reduced by a new $94 excise tax on share repurchases made in 2024. In 1H 2024 compared to 1H 2023, UTMD Ltd in Ireland received EUR 98 less rental income on its underutilized property. &#160;Remeasured foreign currency balances generated about $8 more in net non-operating income in 1H 2024 compared to 1H 2023. &#160;With higher cash balances in 2024, UTMD received approximately $345 more in 1H interest income compared to 1H 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>f) &#160;Income Before Income Taxes (EBT)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consolidated EBT results from adding net non-operating income to Operating Income. Consolidated 2Q 2024 EBT was $4,211 (40.5% of sales) compared to $5,172 (40.2% of sales) in 2Q 2023. Consolidated 1H 2024 EBT was $9,010 (41.4% of sales) compared to $10,291 (40.5% of sales) in 1H 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance, as well as its ability to sustain performance during a challenging economic time.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2024 consolidated EBT excluding the remeasured bank balance currency gain or loss (&#8220;adjusted consolidated EBITDA&#8221;) was $4,942 (47.5% of sales) compared to $6,996 (54.4% of sales) in 2Q 2023. &#160;Adjusted consolidated EBITDA at $10,489 (48.3% of sales) in 1H 2024 was 24.6% lower than the $13,916 (54.8% of sales) in 1H 2023. Approximately 75% of the lower EBITDA was due to lower GP. The rest was due primarily to higher litigation expenses and no CSI IIA amortization expense.  Adjusted consolidated trailing twelve months&#8217; (TTM) EBITDA was $23,208 as of June 30, 2024.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">11</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:344.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2023</span></p>
</td><td valign="top" style="width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:89.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2023</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:344.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">EBT</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;4,211</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;5,172</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;9,010</p>
</td><td valign="top" style="background-color:#CCEEFF;width:89.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;10,291</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:344.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Depreciation Expense</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">172</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">155</p>
</td><td valign="top" style="width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">327</p>
</td><td valign="top" style="width:89.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">310</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:344.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Femcare IIA Amortization Expense</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">501</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">498</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,005</p>
</td><td valign="top" style="background-color:#CCEEFF;width:89.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">981</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:344.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CSI IIA Amortization Expense</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 1,105</p>
</td><td valign="top" style="width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p>
</td><td valign="top" style="width:89.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 2,211</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:344.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Other Non-Cash Amortization Expense</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 8</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 8</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 18</p>
</td><td valign="top" style="background-color:#CCEEFF;width:89.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 16</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:344.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Stock Option Compensation Expense</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 52</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 50</p>
</td><td valign="top" style="width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 130</p>
</td><td valign="top" style="width:89.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 100</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:344.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Interest Expense</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="background-color:#CCEEFF;width:89.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:344.3pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Remeasured Foreign Currency Balances</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(2)</p>
</td><td valign="top" style="width:83.25pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td><td valign="top" style="width:90.1pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(1)</p>
</td><td valign="top" style="width:89.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">7</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:344.3pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">UTMD non-US GAAP EBITDA:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 4,942</p>
</td><td valign="top" style="background-color:#CCEEFF;width:83.25pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 6,996</p>
</td><td valign="top" style="background-color:#CCEEFF;width:90.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 10,489</p>
</td><td valign="top" style="background-color:#CCEEFF;width:89.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 13,916</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>g) &#160;Net Income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Income is EBT minus a provision for income taxes. &#160;Net Income in 2Q 2024 of $3,453 (33.2% of sales) was 17.8% lower than the Net Income of $4,200 (32.6% of sales) in 2Q 2023. &#160;The $747 lower 2Q Net Income was due to $987 lower Operating Income combined with $27 higher net non-operating income, and a slightly lower average income tax provision rate. The average consolidated income tax provision rate (as a % of the applicable period EBT) in 2Q 2024 was 18.0% compared to 18.8% in 2Q 2023. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Income in 1H 2024 of $7,409 (34.1% of sales) was 11.9% lower than the Net Income of $8,414 (33.1% of sales) in 1H 2023. &#160;The $1,005 lower 1H Net Income was due to $1,542 lower Operating Income combined with $261 higher net non-operating income, and a lower average income tax provision rate. The average consolidated income tax provision rate (as a % of the applicable period EBT) in 1H 2024 was 17.8% compared to 18.2% in 1H 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. Except for the UK, in which the corporate income tax rate changed to 25% from 19% on April 1, 2023, the basic corporate income tax rates in each of the sovereignties were the same as in the prior year.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>h) &#160;Earnings Per Share (EPS)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EPS are consolidated Net Income divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value). &#160;Diluted EPS in 2Q 2024 were $0.978 compared to diluted EPS of $1.154 in 2Q 2023, a 15.3% decrease. Diluted EPS in 1H 2024 were $2.070 compared to diluted EPS of $2.313 in 1H 2023, a 10.5% decrease. The decreases in EPS were lower than the decreases in Net Income as a result of fewer diluted shares.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Diluted shares were 3,531,572 in 2Q 2024 compared to 3,638,566 in 2Q 2023. &#160;Diluted shares were 3,579,435 in 1H 2024 compared to 3,637,715 in 1H 2023. The lower diluted shares in both periods of 2024 were the result of shares repurchased during 1H 2024, offset by employee options exercised and a dilution factor for unexercised options just in 2023. Because the average exercise price of employee options was higher than the ending market price of the stock in 2Q 2024, the number of shares added as a dilution factor in 2Q 2024 was zero compared to 10,288 in 2Q 2023. For the same reason, the number of shares added as a dilution factor in 1H 2024 was zero compared to 9,660 in 1H 2023. The number of shares used for calculating EPS in both years was higher than period-ending outstanding shares because of a time-weighted calculation of average outstanding shares, plus dilution in 2023 from unexercised employee options. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Outstanding shares at the end of 2Q 2024 were 3,498,902 compared to 3,629,525 at the end of calendar year 2023. The difference was due to 7,592 shares added from employee option exercises during 1H 2024 and 138,215 shares subtracted from repurchases in 1H 2024. Share repurchases in 2Q 2024 were 95,107 shares at an average price of $67.33. &#160;Share repurchases in 1H 2024 were 138,215, as stated above, at an average price of $67.96. &#160;The total cost of repurchasing shares in 1H 2024 was $9,393,466. For comparison, outstanding shares were 3,628,988 at the end of 2Q 2023. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The total number of outstanding unexercised employee and outside director options at June 30, 2024 was 73,497 at an average exercise price of $77.01, including shares awarded but not yet vested. &#160;This compares to 66,025 unexercised option shares at the end of 2Q 2023 at an average exercise price of $73.78/ share, including shares awarded but not vested. No employee options have been awarded in 2024. &#160;Non-qualified option awards totaling 19,000 shares were made to 48 employees in October 2023 at an exercise price of $77.07. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">12</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>i) &#160;Return on Equity (ROE)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">ROE is the portion of Net Income retained by UTMD to internally finance its growth, pay dividends and make share repurchases divided by the average accumulated stockholders&#8217; equity for the applicable time period. &#160;Annualized ROE in 1H 2024 (before stockholder dividends and share repurchases) was 12% compared to 14% 1H 2023. The lower 2024 ROE was due to the double-whammy effect of a 12% decline in the numerator (Net Income) with a 7% increase in the denominator (average stockholders&#8217; equity). Targeting a high ROE of 20% remains a financial objective for UTMD management.  The increase in average stockholders&#8217; equity was after reductions due to paying cash dividends to stockholders and repurchasing shares.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD paid $1,081 ($0.300/share) in dividends to stockholders in 2Q 2024 compared to $1,070 ($0.295/ share) paid in 2Q 2023. The dividends paid to stockholders during 2Q 2024 were 31% of Net Income. UTMD paid $2,170 ($0.300/share) in dividends to stockholders in 1H 2024 compared to $2,140 ($0.295/ share) paid in 1H 2023. The dividends paid to stockholders during 1H 2024 were 29% of Net Income.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s closing share price at the end of 2Q 2024 was $66.81, down 6.0% from the closing price of $71.11 three months earlier at the end of 1Q 2024, and down 20.7% from the closing price of $84.22 at the end of 2023. &#160;The closing share price one year ago at the end of 2Q 2023 was $93.20. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Liquidity and Capital Resources</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>j) &#160;Cash flows&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $8,038 in 1H 2024 compared to $11,828 in 1H 2023. &#160;The $3,790 lower increase in cash provided by operating activities included a $1,005 lower Net Income in 1H 2024 along with a use of cash to increase trade accounts receivable by $351 instead of a $2,017 decrease in the prior year, and a $2,184 lower increase in amortization expense compared to 1H 2023. Those lower contributions to or use of cash were partially offset by a $441 cash provided by lower inventories compared to a $1,245 increase in inventories in the prior year. &#160; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Capital expenditures for property and equipment (PP&amp;E) were $132 in 1H 2024 compared to $363 in 1H 2023. The amount spent in 1H 2024 was $195 less than depreciation expense in contrast to the prior year when capital expenditures exceeded depreciation as UTMD invested in new equipment and tooling to increase its manufacturing capabilities for biopharmaceutical manufacturing control sensors. &#160;Depreciation of PP&amp;E was $327 in 1H 2024 compared to $310 in 1H 2023. &#160;Future depreciation expense will increase as new equipment is placed in service. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD made cash dividend payments to stockholders of $2,170 in 1H 2024 compared to $2,140 in 1H 2023. &#160;The difference was due to 1.7% higher dividends per share than in the previous year, offset by share repurchases. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In 1H 2024, UTMD received $390 and issued 7,592 shares of its stock upon the exercise of employee stock options. Option exercises in 1H 2024 were at an average price of $51.39 per share. In comparison, in 1H 2023, UTMD received $81 and issued 1,221 shares of its stock upon the exercise of employee stock options. Option exercises in 1H 2023 were at an average price of $66.52 per share. &#160; </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans. The Company intends to utilize cash not needed to support normal operations in one or a combination of the following: &#160;1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>k) &#160;Assets and Liabilities&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">At June 30, 2024 compared to the end of 2023, UTMD&#8217;s cash and investments decreased $3,650 to $89,219 primarily as a result of using $11,563 in cash repurchasing UTMD stock and paying shareholder dividends, offset by 1H 2024 Net Income of $7,409. &#160;The $504 additional difference in lower cash resulted primarily from $836 lower accrued liabilities. At June 30, 2024, net Intangible Assets declined to 13.5% of total consolidated assets from 13.8% on December 31, 2023 despite total assets being 4% lower due to lower cash. UTMD&#8217;s strong 26.0 current ratio at June 30, 2024 was higher than the 22.6 current ratio at December 31, 2023 despite 4% lower current assets as a result of a 25% decline in accrued liabilities. The average age of trade receivables was 32 days from date of invoice at June 30, 2024 compared to 24 days at December 31, 2023 based on the most recent calendar quarter of sales. Both numbers represent excellent receivables collection experience. Average inventory turns declined to 1.8 in 2Q 2024 compared to 2.2 for the last quarter of 2023 due to the lower sales activity and despite a $525 reduction in consolidated inventories. &#160;Both turn numbers which resulted in extra safety stocks of raw materials acquired following the pandemic are too low. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">June 30, 2024 total consolidated assets were $130,032, a decrease of $5,425 from December 31, 2023. Current assets were $3,947 lower than at December 31, 2023 because of the decrease in cash. A $525 decrease in inventories was offset by a $278 increase in total receivables. &#160;Net fixed assets (property, plant and equipment) in Utah decreased $160 as depreciation exceeded new acquisitions. &#160;OUS subsidiary net fixed assets decreased $198 as depreciation exceeded new acquisitions and as a result of changes in FX rates for foreign currency-valued assets in Ireland, the UK, Australia and Canada. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">13</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0">For clarity, the net book value of consolidated property, plant and equipment decreased $358 at June 30, 2024 from the end of 2023 due to the net effect on OUS asset values of period-ending changed FX rates, $132 in new asset purchases minus $327 in depreciation.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">June 30, 2024 net intangible assets (goodwill plus other intangible assets) declined $1,121 from the end of 2023 as a result of $1,023 in amortization and a weaker GBP/USD FX rate on UK intangible asset balances. At June 30, 2024, net intangible assets including goodwill were 13% of total consolidated assets compared to 14% at year-end 2023 and 16% at June 30, 2023. </p>
<p style="font:10pt Times New Roman;margin:0"><br/>Working capital (current assets minus current liabilities) was $98,383 at June 30, 2024 compared to $101,559 at December 31, 2023. Cash balances were 91% of the June 30, 2024 working capital. Current assets at June 30, 2024 compared to December 31, 2023 were $3,947 lower as the result of the $3,650 decrease in cash combined with a $525 decrease in inventories, offset by a $278 increase in total receivables. Current liabilities were $770 lower at June 30, 2024 compared to December 31, 2023 as the result of a $836 decrease in accrued liabilities and $66 higher accounts payable. &#160;The lower accrued liabilities resulted mainly from a $387 lower employee profit-sharing bonus accrual at mid-year 2024 compared to the prior end-of-year 2023 accrual and $805 lower accrued income taxes. Management believes that UTMD&#8217;s working capital remains more than sufficient to meet operating needs, new capital expenditures and projected cash dividend payments to stockholders.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">June 30, 2024 total consolidated liabilities were $5,980, a decline of $1,165 from December 31, 2023. Current liabilities were $770 lower than at December 31, 2023. &#160;Long term liabilities were $394 lower, primarily as a result of the deferred tax liability balance resulting from non-tax deductible Femcare remaining IIA amortization expense being $260 lower.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The deferred tax liability balance for Femcare IIA ($9,084 on the date of the acquisition), was $860 at June 30, 2024 compared to $1,120 at December 31, 2023 and $1,370 at June 30, 2023. Reduction of the deferred tax liability occurs as the book/tax difference of amortization is eliminated over the remaining useful life of the Femcare IIA, i.e. as Femcare pays its taxes in the UK without the benefit of a deduction for IIA amortization expense. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s total debt ratio (total liabilities/ total assets) at June 30, 2024 was 4.6%, at December 31, 2023 was 5.3%, and at June 30, 2023 was 6.7%. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>l) &#160;Management's Outlook&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">As outlined in its December 31, 2023 SEC 10-K report, UTMD&#8217;s plan for 2024 was to</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:18pt">1) &#160;exploit its pre-qualified status to introduce a line of high-pressure process control transducer configurations directly to biopharmaceutical manufacturers;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:18pt">2) &#160;continue to leverage OUS distribution and manufacturing synergies by further integrating capabilities and resources in multinational operations;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:18pt">3)  focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:18pt">4)  introduce additional products helpful to clinicians through product development;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:18pt">5) &#160;continue to achieve excellent overall financial operating performance despite a contraction in revenues;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:18pt">6) &#160;utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/ when the UTMD share price seems undervalued; and</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:18pt">7) &#160;remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The above 2024 plan remains the same, and management looks forward to bringing items 1) -4) to better fruition in 2H 2024. Although revenues are now expected to be lower than projected at the beginning of the year, because of better-than-expected GPM performance, Operating Profit for the year should be consistent with the beginning-of-year projection in UTMD&#8217;s SEC 10-K report, assuming that ongoing litigation expenses remain consistent with 1H 2024. EPS will benefit from share repurchases.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>m) &#160;Accounting Policy Changes&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">None.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">14</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0">Forward-Looking Information. &#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a11"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and in Canada denominated in the Canadian Dollar (CAD). &#160;The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .9336, .9042 and .9159 EUR per USD as of June 30, 2024, December 31, 2023 and June 30, 2023, respectively. &#160;Exchange rates were .7913, .7850 and .7869 GBP per USD as of June 30, 2024, December 31, 2023 and June 30, 2023, respectively. &#160;Exchange rates were 1.4983, 1.4652 and 1.5012 AUD per USD on June 30, 2024, December 31, 2023 and June 30, 2023, respectively. &#160;Exchange rates were 1.3686, 1.3204, and 1.3237 CAD per USD on June 30, 2024, December 31, 2023 and June 30, 2023, respectively. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur and/or by optimizing global account structures through liquidity management accounts.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a12"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 4. Controls and Procedures</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of June 30, 2024. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of June 30, 2024, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style="font:10pt Times New Roman;margin:0;text-indent:24.5pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the six months ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a13"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">PART II - OTHER INFORMATION</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a14"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 1. Legal Proceedings</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD is a party from time to time in litigation incidental to its business. Presently, except for Filshie clip product liability lawsuits still in discovery, there is no litigation or threatened litigation. The Company does not expect the outcome of the Filshie clip litigation will be material to consolidated financial results. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a15"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 1A. Risk Factors</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#333333">In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span>&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">16</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a16"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 2. &#160;Unregistered Sales of Equity Securities and Use of Proceeds</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table details purchases by UTMD of its own securities during 2Q 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:288pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Period</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(a)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased (1)</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(b)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Average price paid per share (1)</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(c)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased as part of publicly announced plans or programs (1)</p>
</td><td valign="top" style="width:96.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(d)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1)</p>
</td></tr>
<tr style="height:1pt"><td valign="top" style="background-color:#CCEEFF;width:288pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">04/01/24 &#8211;&#160;04/30/24</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">63,985</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">67.57</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:1pt"><td valign="top" style="width:288pt"><p style="font:10pt Times New Roman;margin:0">05/01/24 &#8211;&#160;05/31/24</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,854</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">66.93</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:1pt"><td valign="top" style="background-color:#CCEEFF;width:288pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">06/01/24 &#8211;&#160;06/30/24</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">18,268</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">66.75</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:1pt"><td valign="top" style="width:288pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">95,107</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">67.33</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">1) None of the shares were purchased as part of a publicly announced plan and all were purchased on the open market.</span><br/><span style="font-size:8pt">2) The total number of shares repurchased to-date in 2024 through August 8 was 160,000 at an average cost of $67.72/ share, approximately 4% of prior year-end 2023 outstanding shares.</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The frequency of UTMD&#8217;s open market share repurchases depends on the availability of sellers and the price of the stock. The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD&#8217;s continuing and long-term pattern of opportunistic open market share repurchases since 1992.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The purpose of UTMD&#8217;s ongoing share repurchases is to maximize the value of the Company for its continuing stockholders, and maximize its return on stockholder equity by employing excess cash generated by effectively managing its business<span style="color:#FF0000">. </span>UTMD does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">17</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a17"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 6. &#160;Exhibits </b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td valign="bottom" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Exhibit #</span></p>
</td><td valign="bottom" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Title of Document</span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31.1</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z1.htm" style="text-decoration:none">Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31.2</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32.1</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z1.htm" style="text-decoration:none">Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32.2</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0">The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended June 30, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL): &#160;(i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Condensed Statements of Stockholders&#8217; Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">104</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a18"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">SIGNATURES</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:28.8pt"></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd>REGISTRANT&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;8/9/24 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Kevin L. Cornwell&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>CEO&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;8/9/24 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Brian L. Koopman&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:219.1pt"></kbd>Principal Financial Officer&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">18</p>
<p style="font:14pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt CG Times;margin:0">&#160;</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: August 9, 2024</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt CG Times;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-15.3pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: August 9, 2024</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-73.8pt;margin-left:73.8pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>August 9, 2024</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 32.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>August 9, 2024</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20240630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='8.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20240630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureBasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureInventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureInventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureWarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureRevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureEarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureSubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserveDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureSubsequentEventsDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20240630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock Repurchased and Retired During Period, Shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyAccrual' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard and Extended Product Warranty Accrual</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyAccrual' xlink:to='lab_us-gaap_ProductWarrantyAccrual'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Earnings Per Share, Basic and Diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CSI Distribution Agreement Purchase Disclosure</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquireIntangibleAssets' xlink:to='lab_us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, diluted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finite-Lived Intangible Assets Acquired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:to='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work-in-process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition [Axis]</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the description of Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='lab_fil_DistributionRightsAcquisitionAxis'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PolicyTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Policies</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='lab_us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfIntangibleAssets' xlink:to='lab_us-gaap_AmortizationOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding - basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='lab_us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' xlink:label='us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accelerated Share Repurchases, Final Price Paid Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' xlink:to='lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in operating assets and liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Securities Act File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='lab_fil_DistributionRightsAcquisitionDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllocatedShareBasedCompensationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allocated Share-based Compensation Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllocatedShareBasedCompensationExpense' xlink:to='lab_us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='lab_us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='lab_us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:to='lab_us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLiabilitiesNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other long term liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLiabilitiesNoncurrent' xlink:to='lab_us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CooperSurgical Inc</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the CooperSurgical Inc, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CoopersurgicalIncMember' xlink:to='lab_fil_CoopersurgicalIncMember'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:to='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:to='lab_us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from sale of property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:to='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization of Right of Use Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; investments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Remaining years of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Remaining years of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:to='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements and Changes in Accounting Principles</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for (recovery of) losses on accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding - diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2024, 3,499 shares and December 31, 2023, 3,630 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='lab_us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:to='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20240630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Assets' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='16.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='20.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='25.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='27.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='28.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1' use='optional' order='29.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='31.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureBasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureInventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureInventories">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureWarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureRevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureEarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureSubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleOfRevenuesByProductCategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AllocatedShareBasedCompensationExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserveDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProductWarrantyAccrual' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240630.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="utmd-20240630.xsd#idr_DisclosureSubsequentEventsDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' xlink:label='us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' use='optional' order='3.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVE30FJS6]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://www.utahmed.com/20240630' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://www.utahmed.com/20240630' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:srt='http://fasb.org/srt/2024' xmlns:us-gaap='http://fasb.org/us-gaap/2024' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2022-03-31' xmlns:dei='http://xbrl.sec.gov/dei/2024'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
				<link:definition>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
				<link:definition>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShare" id="idr_DisclosureEarningsPerShare">
				<link:definition>000150 - Disclosure - Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventories" id="idr_DisclosureInventories">
				<link:definition>000100 - Disclosure - Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensationDetails" id="idr_DisclosureStockBasedCompensationDetails">
				<link:definition>000220 - Disclosure - Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve" id="idr_DisclosureWarrantyReserve">
				<link:definition>000120 - Disclosure - Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognition" id="idr_DisclosureRevenueRecognition">
				<link:definition>000130 - Disclosure - Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" id="idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserveDetails" id="idr_DisclosureWarrantyReserveDetails">
				<link:definition>000230 - Disclosure - Warranty Reserve (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
				<link:definition>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
				<link:definition>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation" id="idr_DisclosureStockBasedCompensation">
				<link:definition>000110 - Disclosure - Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureBasisOfPresentation" id="idr_DisclosureBasisOfPresentation">
				<link:definition>000080 - Disclosure - Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
				<link:definition>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
				<link:definition>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
				<link:definition>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
				<link:definition>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents" id="idr_DisclosureSubsequentEvents">
				<link:definition>000160 - Disclosure - Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails" id="idr_DisclosureSubsequentEventsDetails">
				<link:definition>000270 - Disclosure - Subsequent Events (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd' namespace='http://fasb.org/srt/2024'/>
	<import schemaLocation='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd' namespace='http://fasb.org/us-gaap/2024'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2024/dei-2024.xsd' namespace='http://xbrl.sec.gov/dei/2024'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember'/>
	<element nillable='true' type='dtr-types:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfRevenuesByProductCategoryTextBlock' name='ScheduleOfRevenuesByProductCategoryTextBlock'/>
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrldt:dimensionItem' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionAxis' name='DistributionRightsAcquisitionAxis'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionDomain' name='DistributionRightsAcquisitionDomain'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CoopersurgicalIncMember' name='CoopersurgicalIncMember'/>
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' name='RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597515068720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,477,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597508837744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; investments</a></td>
<td class="nump">$ 89,219<span></span>
</td>
<td class="nump">$ 92,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">3,668<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,058<span></span>
</td>
<td class="nump">9,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">102,322<span></span>
</td>
<td class="nump">106,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,194<span></span>
</td>
<td class="nump">10,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,640<span></span>
</td>
<td class="nump">13,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">54,030<span></span>
</td>
<td class="nump">54,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(50,154)<span></span>
</td>
<td class="num">(49,350)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">4,946<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">130,032<span></span>
</td>
<td class="nump">135,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,105<span></span>
</td>
<td class="nump">3,941<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,939<span></span>
</td>
<td class="nump">4,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,980<span></span>
</td>
<td class="nump">7,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2024, 3,499 shares and December 31, 2023, 3,630 shares</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(11,322)<span></span>
</td>
<td class="num">(10,658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">135,339<span></span>
</td>
<td class="nump">138,341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">124,052<span></span>
</td>
<td class="nump">128,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 130,032<span></span>
</td>
<td class="nump">$ 135,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597507209440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597507682368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="nump">$ 12,866<span></span>
</td>
<td class="nump">$ 21,740<span></span>
</td>
<td class="nump">$ 25,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="nump">5,127<span></span>
</td>
<td class="nump">8,722<span></span>
</td>
<td class="nump">9,805<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">6,253<span></span>
</td>
<td class="nump">7,739<span></span>
</td>
<td class="nump">13,018<span></span>
</td>
<td class="nump">15,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">3,181<span></span>
</td>
<td class="nump">5,176<span></span>
</td>
<td class="nump">6,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,815<span></span>
</td>
<td class="nump">3,314<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
<td class="nump">6,717<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">3,438<span></span>
</td>
<td class="nump">4,425<span></span>
</td>
<td class="nump">7,321<span></span>
</td>
<td class="nump">8,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">747<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">5,172<span></span>
</td>
<td class="nump">9,010<span></span>
</td>
<td class="nump">10,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">972<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,453<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 7,409<span></span>
</td>
<td class="nump">$ 8,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share (basic)</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding - basic</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding - diluted</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="num">$ (33)<span></span>
</td>
<td class="nump">$ 504<span></span>
</td>
<td class="num">$ (664)<span></span>
</td>
<td class="nump">$ 1,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 3,420<span></span>
</td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="nump">$ 6,745<span></span>
</td>
<td class="nump">$ 9,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597516969136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597515239696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
<td class="num">$ (12,039)<span></span>
</td>
<td class="nump">$ 126,006<span></span>
</td>
<td class="nump">$ 114,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="num">(11,491)<span></span>
</td>
<td class="nump">129,150<span></span>
</td>
<td class="nump">118,018<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="num">(12,039)<span></span>
</td>
<td class="nump">126,006<span></span>
</td>
<td class="nump">114,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,414<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="num">(10,986)<span></span>
</td>
<td class="nump">132,279<span></span>
</td>
<td class="nump">121,761<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="num">(11,491)<span></span>
</td>
<td class="nump">129,150<span></span>
</td>
<td class="nump">118,018<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="num">(10,986)<span></span>
</td>
<td class="nump">132,279<span></span>
</td>
<td class="nump">121,761<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="num">(10,658)<span></span>
</td>
<td class="nump">138,341<span></span>
</td>
<td class="nump">128,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,221)<span></span>
</td>
<td class="num">(2,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,289)<span></span>
</td>
<td class="nump">138,995<span></span>
</td>
<td class="nump">127,742<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="num">(10,658)<span></span>
</td>
<td class="nump">138,341<span></span>
</td>
<td class="nump">128,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,322)<span></span>
</td>
<td class="nump">135,339<span></span>
</td>
<td class="nump">124,052<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,289)<span></span>
</td>
<td class="nump">138,995<span></span>
</td>
<td class="nump">127,742<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,056)<span></span>
</td>
<td class="num">(6,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (11,322)<span></span>
</td>
<td class="nump">$ 135,339<span></span>
</td>
<td class="nump">$ 124,052<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597515331024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 7,409<span></span>
</td>
<td class="nump">$ 8,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for (recovery of) losses on accounts receivable</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of Right of Use Assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and other receivables</a></td>
<td class="num">(297)<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">441<span></span>
</td>
<td class="num">(1,245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(783)<span></span>
</td>
<td class="num">(991)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">3,414<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">8,038<span></span>
</td>
<td class="nump">11,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchased and retired</a></td>
<td class="num">(9,393)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(2,170)<span></span>
</td>
<td class="num">(2,140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(11,173)<span></span>
</td>
<td class="num">(2,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(404)<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="num">(3,649)<span></span>
</td>
<td class="nump">9,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">92,868<span></span>
</td>
<td class="nump">75,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">89,219<span></span>
</td>
<td class="nump">84,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">2,791<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597508456256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2023. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597512912528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(2) Recent Accounting Standards. </p>
 <p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510923824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">(3) Inventories at June 30, 2024 and December 31, 2023 consisted of the following:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:172.9pt" valign="top"></td><td style="width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> June 30, 2024</p>
</td><td style="width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2023</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,334</p>
</td><td style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,685</p>
</td></tr>
<tr><td style="width:172.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:16.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:130.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,435</p>
</td><td style="width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:16.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:122.45pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,503</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,289</p>
</td><td style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,394</p>
</td></tr>
<tr><td style="width:172.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,058</p>
</td><td style="width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,582</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597610921392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(4) Stock-Based Compensation. At June 30, 2024, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2024 and 2023, the Company recognized $52 and $50, respectively, in stock based compensation cost. &#160;In the six months ended June 30, 2024 and 2023, the Company recognized $131 and $100, respectively, in stock based compensation expense.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510706016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> (5) Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2023 or June 30, 2024. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510906704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(6) Global 2Q 2024 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">852</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">167</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,019</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,410</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,042</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,452</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,231</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">315</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,546</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,338</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,045</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,383</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,831</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,569</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,400</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 1H 2024 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,656</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">388</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,044</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,762</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,150</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,912</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,477</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">711</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,188</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,127</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,469</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,596</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,022</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,718</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">21,740</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597511883392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">CSI Distribution Agreement Purchase Disclosure</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#174; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of expenses over the 4.75 year remaining life of the CSI distribution agreement with Femcare Ltd which ended in October 2023.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510923824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><i>(in thousands)</i></p>
</td><td colspan="3" style="width:151.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:151.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:151.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:151.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"></td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,453</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,200</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,409</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,414</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,532</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,628</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,579</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,628</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">11</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,532</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,639</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,579</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,638</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.98</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.16</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.07</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.32</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.98</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.15</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.07</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.31</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597512965504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements<b>.  </b>After June 30, 2024 through August 8, 2024, the Company made additional repurchases of 21,785 shares of its stock in the open market for $1,441, at an average price of $66.15 per share.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597609435408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597511624640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:172.9pt" valign="top"></td><td style="width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> June 30, 2024</p>
</td><td style="width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2023</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,334</p>
</td><td style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,685</p>
</td></tr>
<tr><td style="width:172.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:16.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:130.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,435</p>
</td><td style="width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:16.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:122.45pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,503</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,289</p>
</td><td style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,394</p>
</td></tr>
<tr><td style="width:172.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,058</p>
</td><td style="width:13.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,582</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510724912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock', window );">Schedule Of Revenues By Product Category</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">852</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">167</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,019</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,410</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,042</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,452</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,231</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">315</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,546</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,338</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,045</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,383</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,831</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,569</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,400</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 1H 2024 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,656</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">388</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,044</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,762</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,150</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,912</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,477</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">711</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,188</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,127</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,469</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,596</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,022</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,718</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">21,740</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfRevenuesByProductCategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597512803392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><i>(in thousands)</i></p>
</td><td colspan="3" style="width:151.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:151.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:151.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:151.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"></td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,453</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,200</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,409</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,414</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,532</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,628</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,579</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,628</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">11</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,532</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,639</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,579</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,638</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.98</p>
</td><td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.16</p>
</td><td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.07</p>
</td><td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.32</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:159.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.98</p>
</td><td style="width:10.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.15</p>
</td><td style="width:11.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.55pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.07</p>
</td><td style="width:10.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:70.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.31</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510572016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 1,334<span></span>
</td>
<td class="nump">$ 1,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">6,289<span></span>
</td>
<td class="nump">6,394<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 9,058<span></span>
</td>
<td class="nump">$ 9,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510716480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510925584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warranty Reserve (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Standard and Extended Product Warranty Accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597515385008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="nump">$ 12,866<span></span>
</td>
<td class="nump">$ 21,740<span></span>
</td>
<td class="nump">$ 25,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">4,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">3,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597510927328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-Lived Intangible Assets Acquired</a></td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem', window );">Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System</a></td>
<td class="nump">4.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597514986208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,453<span></span>
</td>
<td class="nump">$ 3,956<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 4,214<span></span>
</td>
<td class="nump">$ 7,409<span></span>
</td>
<td class="nump">$ 8,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140597505319472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 08, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock Repurchased and Retired During Period, Shares</a></td>
<td class="nump">21,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 1,441<span></span>
</td>
<td class="num">$ (6,403)<span></span>
</td>
<td class="num">$ (2,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Accelerated Share Repurchases, Final Price Paid Per Share</a></td>
<td class="nump">$ 66.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481138/505-30-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:0O18=*%N2$ZW,]T57]+>?Z(%!/9T?B:O!:$[?GKB-#A9M%0'SE"?3 [ $\
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MGI4?5XP";"T OS]PKEX>])5J?84^^0]02P,$%     @ P8 )620LA#.C @
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MR/ABH)AL<)G)&[:_)'4^YXHO8IG0OVA?VUH&BDHA65Z#(8(\I=6*[^LZ' &
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MO4U@G!.N#.!\PY@\",I!\P?!^PU02P,$%     @ P8 )6?]K/:+_"0  FE(
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MC=^TF%>;G\'S5AOV@NFZJHO%MK X@D6^?/F=_=@&L5< D98">%L :P7PL*4
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MCSR;\;(1B/_?%T7]ZTWS+,#=XRC/_@M02P,$%     @ P8 )61O9.L/Z!@
M(QT  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RM6>%NXC@0?A6+6YWV
MI&V)G1"@UR)1H+><MA05NOL[!%-\F\2L;6A[3W^V"0DDMMOJ*JVV21A/OAG/
MS#<37SY1]I.O,1;@.4TR?M58"[&Y:#9YO,9IQ,_I!F?REQ5E:23D+7ML\@W#
MT5(O2I,F\KRPF48D:_0N];,IZUW2K4A(AJ<,\&V:1NSE&B?TZ:H!&X<']^1Q
M+=2#9N]R$SWB&18/FRF3=\U"RY*D...$9H#AU56C#R\&?J@6:(GO!#_QHVN@
M3%E0^E/=C)=7#4\AP@F.A5(1R3\[/,!)HC1)'+]RI8WBG6KA\?5!^XTV7AJS
MB#@>T.0'68KU5:/3 $N\BK:)N*=/7W%N4$OIBVG"]?_@*9?U&B#><D'3?+%$
MD))L_S=ZSAUQM$#J,2] ^0)471!8%OCY E\;ND>FS1I&(NI=,OH$F)*6VM2%
M]HU>+:TAF=K&F6#R5R+7B=[#O/\5W(Z&XT'_&YC>WPT?!O/9%S">#,[!X&XR
MN_LV'O;GHZ&Z&8XF,WDUF\L'MZ/)'-S=@$%_]A7<?+O[ <[ PVP(/G_Z WP"
M) /S-=WR*%ORRZ:0.-7;FG&.Z7J/"5DPA>"69F+-P2A;XN7I^J:TKS 2'8R\
M1DZ%?V^S<^![7P#R4&# ,WC[<M\!QR]\[FM]OD5?X;,9N+F_NP5WT]%]?SZ>
M_ 7Z@_GX^W@^'LU,7MMK#<Q:5;Y?\$T4XZN&3&B.V0XW>K__!D/O3Y/)'Z3L
MQ %!X8# I;TWD>6)9#%-L<G,_=I0KU55:-=K!U[WLKD[AE\7Z@0P*(1.8+4*
M6"WGOO27_\B$DS5*<""H+%(QS6*28) 5>-5S=1='? TVC.Z(C%"P> &RKK)(
MD.QQ7YB((-@8^:V/W,,/4G;BK+!P5NC<PR&62F,2J6)L,G2_NG6T03YJ5S;1
M( ,]\QZV"UAM)ZQ^2ID@_UIAM6NOA#JI3W#5A7SDM<W .@6PCA/85 6+)C_)
MO>"S"JX=9C)P5G^ A'*..="L%M.MBC_Y.R:[:)$84Z13 W@65FPPB*#0;$*W
M,*'[9M]*W$!SOKIXX!CTI0G"&/+=&A)4!>L4.<$*O9+8O%<"=(49D]EYR-SH
MV9R2N9X35_EA4(%HDH*^)2C@$?U")\J9H/'/,]6(+(&$*;LSOO<O?E;7QMW/
M59X$L0^K> U"GB6Y("KA(B?<>?0,%CC#*R) ) 0CBZU00:KJ(G[&+"8R%&1$
M<&66+(K*%+/347W+O:H)=9FNQ8"2>N$KW+N.LD>9:[)#.2K9.G:![%9 0J(%
M2:SE&WXH!W^4ME-?E"P,W33<KQ<;[0,JUI@=/31[(C 4F&ZUPANDD!=8>!J6
M1 V=U-8;9SO)TI39=JE5>VL0U!*D+G0&4="R8"MY$;J)<<KP)B++0P+S(Y?&
M6UF0,I''FQ%YG1*/$.7 #;1I 5VR)GR%-@^AL(E>;*0#Z[085@NY00;:VC)8
M4B=T<Z=$Q[:X=*D1G8'PVITJLYNDNEUH 5@2(W0SXYR** %1V3\:$=99+D35
MOM8@Y%L;6U22(7*3X>3_]*RH3GT=S^]4D!ND(.R@C@5ZR9 (OFM:&D^^CV9O
MF):0DWC?6ZH_2MNI$TK>16[>E=VCW"SQHHL)_K4E&Q5F1K/KI"G[%%3=+(.4
M'UK*""K9%3D92]9E(>F5:"*QUKA<Q\F[JS7.(&/I75!)=\A-=]*',<9+#E:,
MIH!'B>Y4-F_WK('+JGQGD+'A+LD.N<FNR-TMU]VL_+?#_"UY:V(X6.VR3%+V
M4"AI$(7O2MN;\:0_&;PA;9WL^NZT_2!MITXH:16Y:?4TY CGVRB+==C)7C^5
M7?Z^3SYS=<K(,(UV:YM8%^I86 V5M(O<M#LXQKC9LGBMQQ25* P+PJK?YG*\
M)HKUNU4F-HC9,J6D8>2FX6GTHI)7^7=)%,U9/C^B.LF>(=BN.=4H%EA@^B49
M^V\DXT-"KT@FX^+UA/9-,RB$[:IO37+(:UF&)[^D8M\]K(Y6*QQK]^+G6 ]2
M0#80&,3Y4"6#1=EEA%X?1\\"KSID&Z1@:(ECOR1/WTV>^>=&AF7X*G=KWZLH
MUA>JYN\D&5BZ-M_(E$&U;S.(=5NAY?. ?_2EV$VH PU5R)G[D629BA!%69@1
M:LP]OTZ;7=0)JZV:0:S=\EK(@K9D6-_-L >T6$T\3IQUFNQT$:PYU2 6A- 6
MQR6C^FY&U3CUD+;<,N54.9WE:/77N=>^&/EURD3M;G7 -$FU LMW+;\D5M\]
M7[X.7F#)9<86)E<=&HMNCMHELH?</#IN2C%[U*=P'.@)<G\H4SPM3OKZ^GRK
M\OP:7@SVYW6EFOWQX6W$9,!SD."55.F=MZ47V?Y$;G\CZ$8?:BVH$#35EVL<
M+3%3 O+W%:7B<*->4)R+]OX#4$L#!!0    ( ,& "5GX(VFQ<P,  (,'   8
M    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULC55A;^,V#/TKA =L+="+$R?7
M';HDP*7=L-O0(;M>M\^*Q<2ZDR6?*#?M?OU(.?%Y0!KL2V))?(^/%$G-]SY\
MH0HQPG-M'2VR*L;F)L^IK+!6-/(-.C[9^E"KR,NPRZD)J'0"U38OQN/KO%;&
M9<MYVEN'Y=RWT1J'ZP#4UK4*+RNT?K_()MEQXZ/955$V\N6\43M\P/C8K .O
M\IY%FQH=&>\@X':1O9_<K&9BGPS^,KBGP3=()!OOO\CB@UYD8Q&$%LLH#(K_
MGO 6K14BEO'UP)GU+@4X_#ZR_Y)BYU@VBO#6V[^-CM4B>Y>!QJUJ;?SH][_B
M(9ZWPE=Z2^D7]IUM4610MA1]?0"S@MJX[E\]'_(P +P;OP(H#H BZ>X<)95W
M*JKE//@]!+%F-OE(H28TBS-.+N4A!CXUC(O+E2)#X+>P#DCHHI)<S?/(U&*0
MEP>:54=3O$)S#??>Q8K@9Z=1_Q>?LZ1>5W'4M2K.$O[6NA%,QU=0C(O9&;YI
M'^<T\4U?X?O#1Z13<76PV6F8M,0--:K$1=9(@L(39LOOOYM<CW\Z(VK6BYJ=
M8___R3]/<S&YA$\50NM4JTU$#5OCE"N-LD!,BMQ$D:!23P@;1 <<2J,"VQEI
MB]('S=;(E1<KB$QD',70IK8AB!ZD_F$R?O,G**=!>W ^LE%I6XV@K)40.EPW
M)5*[L26;(6A#I?74<HC<Q5];(XXW+\EQZZ)Q.];#9*:Q;+%#AX$ITSDVL1,I
MY(\NA?8@ =%( B8<AD>5;RTS(\AP$E3IW>?6==W?QW8R-4>Q=(SJF]>H*KA'
M;4I&K(/7G!:Z@@^N',%%]OCI_BX#'R 3VUM?-\J]9)?,YUJVYS3[$('='S/X
M.W"&$O$+J@ HW0)W6&*]P0#32:KWZ8CYDY%OC!/UG-]:.1Z2(O<J'4GZDCM)
MX,F@AA>D]&>>)=W^!>>%ZRYEWCO.-+,[N3<17+8AR,$ < F.!1+QS)9BZ,:W
M^8=3J4Q@^"#T'V@@I?%D^E+@V^<YF8J='Y20:H1O\9;=H2OYMFLI!KZ)@%WJ
M?4N,(\!G*0-@S!NJY+2W9-9]A;PC-Z='I_HQ'PS&&L,NC7^"5'C=C.QW^Q?F
M?3=8OYEWS].]"CON"["X9>AX]./;#$(W\KM%]$T:LQL?>6BGSXH+$8,8\/G6
ML\S#0AST[^[R7U!+ P04    " #!@ E9N0UI?Y "  #4!0  &    'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;+54VV[;, S]%<(#A@TH8M?)TJ)+##39AFU
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MQ3#D/L9F.^X 6AAV!B(( AK:M"4CAEHZRO%DGIU2E+V/!KYM&B713X FH:.
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M^EV_W- /!HUWH/.UIO=[,'R \9>U^ %02P,$%     @ P8 )6<EAN#KS @
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M'"H,*_HEH/$':+_0U%:KB;^@_\E,_P)02P,$%     @ P8 )65<>/-]8 P
MW0<  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULC57;;ALW$/V5P18H
M$D#9NV3)E01$<8JV0 PC;IMG:G=62YA+;DFN9?]]A]R+Y406\L+;S!R>PR&'
MZZ/2#Z9&M/#4"&DV06UM>QU%IJBQ8294+4JR5$HWS-)4'R+3:F2E#VI$E,;Q
M(FH8E\%V[=?N]':M.BNXQ#L-IFL:II]W*-1Q$R3!N/"5'VKK%J+MNF4'O$?[
M3WNG:19-*"5O4!JN)&BL-L''Y'J7.W_O\"_'HSD9@U.R5^K!3?XL-T'L"*'
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M:W-H965T<R]S:&5E=#$W+GAM;(U4VV[;, S]%<(#A@TH8M?)NB%+##39AFU
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MT.C\:Q: [ONWWUC5^)Y9*4L=Z)<5?7FHG0.=KY6R^XT+,'RB^5]02P,$%
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M-%W, M#=4.TV5C5^D-TJ2V/1BQ7]AU [!;HOE;+#QCD8_VS;/U!+ P04
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M!   &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q]5.]/VS 0_5=.$=)
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MWOQ.O9U_-,;-/<\UWO].JOWXKIFOGY;/S04[$\X:?F2<?@%02P,$%     @
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MC%3VX,^Z/S6S3U!+ 0(4 Q0    ( ,& "5D'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ P8 )6;$+
M0P[O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ P8 )69E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #!@ E9OU!T@=<%  #6
M'@  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ P8 )66%8[/30!0  3A<  !@              ("!&PX
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,& "5DD+(0S
MHP(  &0'   8              " @2$4  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #!@ E9/CI58>\%  "0&@  &
M@('Z%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ P8 )
M6;+JLZ^] @  + @  !@              ("!'QT  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( ,& "5G_:SVB_PD  )I2   8
M      " @1(@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #!@ E9&]DZP_H&   C'0  &               @(%'*@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ P8 )6?@C:;%S P  @P<  !@
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M970Q,BYX;6Q02P$"% ,4    " #!@ E9G";M4/T"  "^!@  &0
M    @(%$00  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M ,& "5G)8;@Z\P(  ' &   9              " @7A$  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ P8 )65<>/-]8 P  W0<  !D
M             ("!HD<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #!@ E9[4HAP_D!  "C!   &0              @($Q2P  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,& "5G,7QGOD@(
M ,L%   9              " @6%-  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ P8 )69DX*B)C @  4 4  !D              ("!
M*E   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #!@ E9
M!PAN$14#  #;!@  &0              @('$4@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,& "5FP\JPB_0(  .4&   9
M      " @1!6  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ P8 )68OGQE*" @  P@8  !D              ("!1%D  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #!@ E9(7&=[(<"  "]!P
M&0              @(']6P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( ,& "5FH,BXC% (  .H$   9              " @;M>  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ P8 )6:F26"W;
M!0  QRT  !D              ("!!F$  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #!@ E96)0RP6P"  #\!   &0
M@($89P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,&
M"5D('UD<Y@,  &D1   9              " @;MI  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ P8 )6<*Q8#<! P  3PD  !D
M         ("!V&T  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " #!@ E9/!M5P00#   M$   #0              @ $0<0  >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ,& "5F7BKL<P    !,"   +
M  "  3]T  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,& "5G>X8NB\P(  +X2
M   /              "  2AU  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #!@ E9?SW?:4<!  #8$   &@              @ %(>   >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #!@ E9VG)9V'@!  "Q$0
M$P              @ ''>0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..(P C &P)  !P>P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>133</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve</Role>
      <ShortName>Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - Warranty Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserveDetails</Role>
      <ShortName>Warranty Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="utmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000270 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="utmd-20240630.htm">utmd-20240630.htm</File>
    <File>utmd-20240630.xsd</File>
    <File>utmd-20240630_cal.xml</File>
    <File>utmd-20240630_def.xml</File>
    <File>utmd-20240630_lab.xml</File>
    <File>utmd-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="440">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20240630.htm": {
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "utmd-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "utmd-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 131,
   "keyCustom": 2,
   "axisStandard": 3,
   "axisCustom": 1,
   "memberStandard": 4,
   "memberCustom": 7,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 83,
   "entityCount": 1,
   "segmentCount": 11,
   "elementCount": 181,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 440,
    "http://xbrl.sec.gov/dei/2024": 29
   },
   "report": {
    "R1": {
     "role": "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "E24Q2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E24Q2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "E24Q2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E24Q2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "E22_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y23Q1_StEqComps-CommonStock",
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureBasisOfPresentation",
     "longName": "000080 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples",
     "longName": "000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureInventories",
     "longName": "000100 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation",
     "longName": "000110 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve",
     "longName": "000120 - Disclosure - Warranty Reserve",
     "shortName": "Warranty Reserve",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognition",
     "longName": "000130 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure",
     "longName": "000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure",
     "shortName": "CSI Distribution Agreement Purchase Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShare",
     "longName": "000150 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents",
     "longName": "000160 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies",
     "longName": "000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables",
     "longName": "000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)",
     "shortName": "Inventories: Schedule of Inventory, Current (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables",
     "longName": "000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables",
     "longName": "000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240101_240630",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
     "longName": "000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)",
     "shortName": "Inventories: Schedule of Inventory, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "E24Q2",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E24Q2",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensationDetails",
     "longName": "000220 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserveDetails",
     "longName": "000230 - Disclosure - Warranty Reserve (Details)",
     "shortName": "Warranty Reserve (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "E24Q2",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E24Q2",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
     "longName": "000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q2_ProductOrService-Obstetrics",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
     "longName": "000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)",
     "shortName": "CSI Distribution Agreement Purchase Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "longName": "000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q2",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails",
     "longName": "000270 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "D240701_240808",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240701_240808",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accelerated Share Repurchases, Final Price Paid Per Share",
        "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r407"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts &amp; other receivables, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r448",
      "r449",
      "r450",
      "r451",
      "r472",
      "r507"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total adjustments",
        "totalLabel": "Total adjustments",
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r186"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization {1}",
        "terseLabel": "Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r151",
      "r154",
      "r399"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r62",
      "r76",
      "r93",
      "r125",
      "r127",
      "r132",
      "r133",
      "r140",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r205",
      "r209",
      "r222",
      "r283",
      "r341",
      "r396",
      "r397",
      "r407",
      "r431",
      "r466",
      "r467",
      "r474"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r79",
      "r93",
      "r140",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r205",
      "r209",
      "r222",
      "r407",
      "r466",
      "r467",
      "r474"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Blood Pressure Monitoring and Accessories",
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash &amp; investments",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r73",
      "r389"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash at beginning of period",
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r46",
      "r92"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net increase in cash and cash equivalents",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r46"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r428",
      "r429",
      "r448",
      "r449",
      "r451",
      "r472",
      "r506",
      "r507"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options",
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options, shares",
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r329"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r329",
      "r347",
      "r507",
      "r508"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2024, 3,499 shares and December 31, 2023, 3,630 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r285",
      "r407"
     ]
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r81",
      "r83",
      "r87",
      "r279",
      "r292",
      "r293"
     ]
    },
    "fil_CoopersurgicalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "CoopersurgicalIncMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CooperSurgical Inc",
        "documentation": "Represents the CooperSurgical Inc, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r243"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r64",
      "r447"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r284"
     ]
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit attributable to exercise of stock options",
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability - Femcare IIA",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r183",
      "r184",
      "r185",
      "r402"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "auth_ref": []
    },
    "fil_DistributionRightsAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "DistributionRightsAcquisitionAxis",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Rights Acquisition [Axis]",
        "documentation": "Represents the description of Distribution Rights Acquisition, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_DistributionRightsAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "DistributionRightsAcquisitionDomain",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Rights Acquisition",
        "documentation": "Represents the Distribution Rights Acquisition, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "fil_DomesticUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "DomesticUsMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DomesticUsMember",
        "documentation": "Represents the DomesticUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, basic",
        "verboseLabel": "Earnings per common share (basic)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r124",
      "r200",
      "r203",
      "r220",
      "r221",
      "r280",
      "r294",
      "r393"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, diluted",
        "verboseLabel": "Earnings per common share (diluted)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r117",
      "r118",
      "r119",
      "r120",
      "r124",
      "r200",
      "r203",
      "r220",
      "r221",
      "r280",
      "r294",
      "r393"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r121",
      "r122",
      "r123"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r67",
      "r84",
      "r85",
      "r86",
      "r94",
      "r95",
      "r96",
      "r100",
      "r107",
      "r109",
      "r111",
      "r126",
      "r141",
      "r144",
      "r157",
      "r176",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r201",
      "r202",
      "r203",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r234",
      "r238",
      "r291",
      "r303",
      "r304",
      "r305",
      "r317",
      "r366"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r147",
      "r153",
      "r399"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r153",
      "r247",
      "r399"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r148",
      "r278",
      "r397",
      "r398",
      "r406",
      "r407",
      "r460",
      "r461"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r40",
      "r61",
      "r93",
      "r140",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r222",
      "r395",
      "r396",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r466"
     ]
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gynecology/Electrosurgery/Urology",
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r58",
      "r61",
      "r281",
      "r289",
      "r395",
      "r396",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r65",
      "r110",
      "r111",
      "r125",
      "r130",
      "r133",
      "r190",
      "r191",
      "r194",
      "r295",
      "r403"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r48",
      "r445",
      "r469",
      "r470"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {1}",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CSI Distribution Agreement Purchase Disclosure",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r155",
      "r156",
      "r384",
      "r385"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r462",
      "r463"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {2}",
        "terseLabel": "Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r391"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "totalLabel": "Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r390",
      "r407"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r93",
      "r140",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r206",
      "r209",
      "r210",
      "r222",
      "r328",
      "r394",
      "r431",
      "r466",
      "r474",
      "r475"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r57",
      "r287",
      "r407",
      "r446",
      "r459",
      "r473"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r72",
      "r93",
      "r140",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r206",
      "r209",
      "r210",
      "r222",
      "r407",
      "r466",
      "r474",
      "r475"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "fil_NeonatalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "NeonatalMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neonatal",
        "documentation": "Represents the Neonatal, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in financing activities",
        "totalLabel": "Net cash used in financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r49"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements and Changes in Accounting Principles",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r97",
      "r98",
      "r101",
      "r102",
      "r112",
      "r113",
      "r138",
      "r142",
      "r143",
      "r198",
      "r199",
      "r201",
      "r203",
      "r216",
      "r218",
      "r237",
      "r239",
      "r240",
      "r244",
      "r245",
      "r246",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "fil_ObstetricsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "ObstetricsMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obstetrics",
        "documentation": "Represents the Obstetrics, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income",
        "totalLabel": "Operating income",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r395",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Right of Use Assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r54",
      "r311",
      "r312"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r407"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r291"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r223",
      "r230"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "fil_OutsideUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "OutsideUsMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OutsideUsMember",
        "documentation": "Represents the OutsideUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired {1}",
        "negatedLabel": "Common stock purchased and retired",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "negatedLabel": "Intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock - options",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r243",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r387",
      "r400",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r464",
      "r465",
      "r468",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ]
    },
    "us-gaap_ProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standard and Extended Product Warranty Accrual",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r162",
      "r165",
      "r166"
     ]
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureWarrantyReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warranty Reserve",
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r243",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r387",
      "r400",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r464",
      "r465",
      "r468",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income",
        "totalLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r80",
      "r82",
      "r90",
      "r93",
      "r99",
      "r107",
      "r110",
      "r111",
      "r140",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r200",
      "r203",
      "r204",
      "r207",
      "r208",
      "r221",
      "r222",
      "r281",
      "r290",
      "r316",
      "r349",
      "r364",
      "r365",
      "r404",
      "r405",
      "r430",
      "r442",
      "r466"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r236",
      "r282",
      "r288",
      "r407"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for (recovery of) losses on accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r145"
     ]
    },
    "fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System",
        "documentation": "Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r385",
      "r396",
      "r476"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r52",
      "r286",
      "r306",
      "r310",
      "r314",
      "r330",
      "r407"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r94",
      "r95",
      "r96",
      "r100",
      "r107",
      "r109",
      "r111",
      "r141",
      "r144",
      "r157",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r201",
      "r202",
      "r203",
      "r211",
      "r213",
      "r214",
      "r217",
      "r219",
      "r232",
      "r234",
      "r303",
      "r305",
      "r317",
      "r507"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r125",
      "r128",
      "r129",
      "r131",
      "r133",
      "r134",
      "r135",
      "r137",
      "r177",
      "r178",
      "r243"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r386",
      "r392"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r33",
      "r34",
      "r35"
     ]
    },
    "fil_ScheduleOfRevenuesByProductCategoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.utahmed.com/20240630",
     "localname": "ScheduleOfRevenuesByProductCategoryTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenues By Product Category",
        "documentation": "Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r319",
      "r320",
      "r321",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388",
      "r401",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r419",
      "r424",
      "r468",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r30",
      "r31",
      "r67",
      "r84",
      "r85",
      "r86",
      "r94",
      "r95",
      "r96",
      "r100",
      "r107",
      "r109",
      "r111",
      "r126",
      "r141",
      "r144",
      "r157",
      "r176",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r201",
      "r202",
      "r203",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r234",
      "r238",
      "r291",
      "r303",
      "r304",
      "r305",
      "r317",
      "r366"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r319",
      "r320",
      "r321",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388",
      "r401",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r419",
      "r424",
      "r468",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r126",
      "r234",
      "r243",
      "r313",
      "r318",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r425"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20240630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r126",
      "r139",
      "r234",
      "r243",
      "r313",
      "r318",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r425"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26",
      "r27",
      "r52",
      "r181"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r30",
      "r31",
      "r52"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option compensation expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedLabel": "Common stock purchased and retired, shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26",
      "r27",
      "r52"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEventsDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26",
      "r27",
      "r52"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r30",
      "r31",
      "r50",
      "r331",
      "r347",
      "r367",
      "r368",
      "r407",
      "r431",
      "r446",
      "r459",
      "r473",
      "r507"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, value",
        "periodStartLabel": "Equity Balance, value",
        "periodEndLabel": "Equity Balance, value",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r67",
      "r68",
      "r85",
      "r94",
      "r95",
      "r96",
      "r100",
      "r107",
      "r109",
      "r141",
      "r144",
      "r157",
      "r176",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r201",
      "r202",
      "r203",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r219",
      "r225",
      "r226",
      "r231",
      "r233",
      "r238",
      "r304",
      "r305",
      "r315",
      "r331",
      "r347",
      "r367",
      "r368",
      "r373",
      "r430",
      "r446",
      "r459",
      "r473",
      "r507"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of stock options",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted shares",
        "verboseLabel": "Shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r120"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.utahmed.com/20240630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares, basic",
        "verboseLabel": "Shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r120"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481138/505-30-25-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001811884-24-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001811884-24-000018-xbrl.zip
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M"%SY R2:\40,6F]SGJ8\$\_)F%IDI&I@]ZFFP9>XWH/NP%^.BLX ^ "/S+L
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M3E4(PQT\:\P@Q/:E[@P8R=TLMT1HNQ,S\_S!)0].SEVZ%,<3LJPV=\GJ<8%
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M+CT[N0*!TZ<IP/)J3L_X? P\/;AZZ&GB.4>/Y6@$C@2V_I1/:2DP2QR-UEO
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M&96LPR-/N)T</()'!P'PD2?K(G9&$E(@T=;A W!JA59-/M0MS;&35N42[FH
MX&3C80II8D7J04+2HF$BTR6-W;HDEJ6%+>'/TL*!HCZK"M.5)/;/!](<5_X
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MB!=18KVRL5-%GAO+P1,$/'EB-55YLR3@%.9VLTJ>B(T#4"EI\7I0-'6$6]6
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MGBSHCI<O9=(GD_FG5KL')?*#+D?JD."2]R)(7XMXBB#Z/E.<&AV-X%.^6+\
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MC/J#6,.GR+C<Y#ZEZ"DWS%DL7UEI$NS*+,S>YX7V2Z*V>$=3Y#Z6Z-\0*WY
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M2U8"4</\-$6R(H[..!I(!_Y3_*-EJ*N@#C\W![N]9@XJO"4#/FW+,8X[_32
M*+#8&NLP>3\TY$HV9 2S%&^N"&VNV3"K_]2&+0=#GP(@U5N<9_!2G.=@B_-4
MAZV4!<^JQU:J^G/(T_[YS]5XR@W:$+_ *O<,J[3-_@!X?K>/^5XI5Y-GJW,U
M=519C=$-$#N>1U/* 2348[CBW/<=U/]W1K5=JF/)8M,Z%L@U&ZV&;;%IC4:
M2: 7[G5U6"^""CY03M9&""_K[QO"N_(W:D <=1FAGN.H:^%=3L^F409/PKML
M1,0/-#394^@N>XB(GZ&FSM4%[Y(;MQ6\RY*P:(1W=4S+LLK!NX3P*P/JTNYG
MT:=-W7,I-%[.4W!2#-T3L"K;M!"(9753'&KM/KX<79M]H.R,*6XA&*R3(>T*
MX5G.&GB6G%H!/,MZI4VHC"^%OK;D<-L#K*MY4"BYK;A3<@=?H% '#(42!WK
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M,L9(Y'0+OE^_9VKU;H!:L$(8EY>[^/[5-,Z^OZ?!SL_>\\W%ZY $N#+@E0]
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M!([MD_W,=/<WM70Q@BTNY#Y.Q"I_(FONYAYFVJ]5;,H%(B)[%ZLC0*P.4V!
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MI#A*&P+@2;QF\0SG!=3X5O[$H<'<,>PUTB0^@5X*@QPU,CP3/FJ3<Q<W=(;
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M)6MG&5?6/,UKI@ +::OB*[!5QX_&.<<P:@".1Z%7=S_2SDN X] #',@B3_\
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M@TT8C?,3@82<;J#JGNF8]*G(*M$V2\^ZE>F98AB?$D5D8S:]+YCH4Z6:$>-
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MR@P1/EHAD%O"6&( BIF:]1' [HA+08QP:51!3>XT.9-0P;H !/F)N9!2B+O
MZ8V;6$YO/?Z\-%I6!+?;MV(*^@4./#\.&U_07;O5:3:ZZ*'?:STVAX-3U+EO
MEE"S=S_H=3NMQK#=TB^M]OT G@9#:+AKWP]1[Q8U&X,OZ+;;^YH[A3T_6N:Q
M+9"6"2P=ILELF4]<KX_6E9B"'NZ3!ZRKY2E1&NE5\;J#I"5B/[XZ8M?B%+I[
M=VU 7V.<^T8B:)N2PDNXDP0R-":"F'%_"(0SA>IP";DID _ MLS!'U+!W1QT
MT"IAM*",8M(K"+E1#PWX&^SIO:O!E!!U?*QOIV8)\^JKP_RFT6W<-]MH\*7=
M'N8!GJ4O'&U^F\7/L[%X;N%7IW!+278X$4NUEEY>/2RAY[7<<8NP%CL?A&\Q
M\=EQR["Y?3.HU<T:WI1[+A&R_2.@:GYLJ;Z!HB6A7V13J0^&O>9O7WK=5KL_
M^"N><?EWU/['8V?X1^X<>RT8[[]2;"O"TP&];8DX-TMH%NX$VN_CWP9SVTQ!
MR'38F L_:9I]H"VQ%IHG0EY]U#O0(26T0BJW42)T].$/V1L_K*B[*6XV@5FL
MDMZ,- 3TK+=*(K=&5@>0MF\O'TO24NND=S4S.GZ4;T9G?OHHXT-%MN"__!/.
M"N6NL'//;QG849^\F4>5;1-*T0E\:%B^?XZB9\D1Z37,#?N(*TFB-XX!)+J9
M1S<,%(HYYE](V7K$]GGC&'*6<CJ='([TAWRNR&IS*YO]+-O,\"'++:S<XLFO
MX& DR8\ 5&WKA:7-)Z62,)9039\N7V*C$#VWP0X;V ZM;0&U3*;I4]@IB_R?
M39!7Y>5%*7A>O4-U1?T9%PJ%U_ZZW#$=X4TLN<?U+?,N2R_2+2"V\:Z?]?)7
M>8<(&Z[#Q)?8BOIY&^.-M]Y>P:QJ<!?7\33/:O'L'$3?2^7U>XB[^,M8\-1=
MO#+QE-1OY@;1-M;I*WR'<UR]U!=RC5KVX[QV)W!O[LFK?OK!RF_S!4'#+[J5
MBO!(*H$=52\H$1 @0CU/%SGQN[FI55C<5ZRYW,>4=6!2U5%30!)R@J+*["=]
M%CR8U0OFPFF- D@!A<\S(BAWAR&I0!C="CI+%<;4^]:"B1QH.(_RCO@C(D)-
MZH54^UL3O!<H25V2E#O9_.;$!@I$">HDY4ZVOS7![PEG6&%O7>Q$ZUL3^O.<
MP;>&QR?SMD<<)?1D.B%B_BA,X[HN^P&_-15O/,Y=O=2JZX0[#C,U%Y1-&LQM
M. ZTFNW(=44/05E3=Y=ZBKPH(.Y\SU3#?;Y&8\:QB@?AO,*DH=QZ-Y]-=BKK
MJII+@;C^9PN=_3/SRF&!OOZG";+A_ BH-*58XX7*1:K>"?C6?-8J<<OPVTNY
M"/2MJ=?D^@:SSA[Z<QH^EM?#;UOW'J$6<G>)0WW S%+F/M'# -[\!\%"]L;M
M%\<+)'TBCX.T"6ZYN"6^@R&%W,('R)22ID=G@[DT[$(MLR.X][CXG,$7D9AG
M,C!AWR@\V04=9$35JHE]X&;VA_O$(:"6"^FS3Q05Q'V<<=9^(<*ADD0G"GHS
M354N7>!UZ'L/A=0[+C)CKWZ5S&;OYUC%(R*@_E4YK-*OW_T74$L#!!0    (
M ,& "5GR( [SMPD  .%]   5    =71M9"TR,#(T,#8S,%]C86PN>&UL[5UM
M<QHY$OZ<_(I9WP?NJH+QRR87N^)L8< I]IS@PLEFZZZNMN29QF@S2)RDP;"_
M_EH#@V=@-"]VS B<*I=MH"5U/T^KU7H;WOTR'?G.!(2DG)W5#O</:@XPEWN4
MW9[5J.3UMV]?G]0/:[^\?_GNIWK=N1+<"USPG)N9TVE_:/9E0!4XD@_4'1'P
MRFEZ$\*T0(N/QH$"X709XQ.BL 'Y"E^X^Z_PL_%,T-NA<O[>^H=S='#PMGYT
M</2S\Y^KJ]__=?*I?7G\Z[^__M8Y/KCX]?K-?_>=N[N[??!NB0A;VW?YR*G7
M42.?LF^G^M<-D>"@*4R>[0V5&I\V&KK,]$;X^US<-K")XT8DN/?RQ8M0]G0J
M:4+^[CB2/FS\_O'RVAW"B-0IDTK;%):3]%2&;U]R-S2J0(..44*_JD=B=?U6
M_?"H?GRX/Y7>O9H#ZB=:"109CL#3.#0T;@=OC@_NI75UY5!8*[' X?#DY*01
M?AH3QLH\M92.U_VZ,?\P*4PS=%DB^_[EBSF9@OO0AX&C_W[I=W/-;FC!!O7$
M']>**!@!4U]0["-XU"7^W%N51*]KH?MQGWHHY)T37[=Z/010>TYHX*F:C>%L
M3]+1V(?HO:& P=E>H$9>/6I/$_.WQS376)J*!=S #WWH$E\G]("I N:!%VFB
MK=P %JC;0CF?NW&%:K[V=BYJ<61J6A\9.<& R)N0V4#6;PD9AVHUP%<R>B<$
M,01P\<8?32E!R58@!.H:U>V3&_#/:NDRC4VKV")RV&2>_M/Y7T GQ$<U9%.U
MB! SC)*_$3\ @^K%RL9,BKE$4R2M(\*-6L%_0W^H&?O50J(A@]$HK*V.87,4
ME1\(/C+A&[7)RUKA!!(UXF/=&O%K#A<>B,6(<@<ZUL]?;)S INOR !7N@PNH
M_(T/GT#EN%Q6$=OIRK8WG:6CREGJL@GJQ\4,E36PDA"QG86D/>FH'U>.>D\-
M010)PBF"MC.09ELZ#S]7SL-<S<P!T Z\4P-.$8RK'P<P_QF#4+,KS'<4CF=Z
M+!OK',D<<3*+6,M'MJ&V#@ ?./?NJ.\;J%A^;"WL]P;8&NV[#"=;MQ0S@KD5
MZ ^=J>L'>K*? W^AHM924\QP6P>'"\K0Z$LZ 6_5D ^"2].PD5NL8KK*>&.<
MS'PX;!V!,C3'I#T8:0; :XZX4/2O$+[RU)HJVCVRC9 5&.'JE?!_2<D-]:FB
MD)-MIPA6-FV^(C,]ARPV85X1KMCIS'BGS9=7#;4UBJ"^(@"OL#.9Y;>%'I.Y
MMJ:R,5WS.[A%+*3!7QSWZGM&&P: *GJ?R32F=C2\X$QH=0A9?6U@Z_'UVLWQ
M=\#-UJX8+@+%C/K$F9N_T)5>P&X2LRRU=4+:&X- L]GM)1 )D?*S?))RRUG.
M5;[=MDY&HUC192X?03)BF!?2\DK935>NS>EDO:Z<K)B>&,6O%7>_#;F/RDF]
M)JAF^=E)>C%[Z,HTRY#'V)O %&9H-SA)D[(UD6CQT8BS4./,'?]5L8II*4;$
MNG&V]I#8HD^8\.A#9@*&P"2=P#P^7W(ISV' A8[4A^9)<<EZMH+(!\!C:X=K
M>AZ=*W5%* Z]+3*FBO@Q5S51FU]P.[@L ("MB7T?%*$,O X1#-/<^%HM)E/4
MI:9$L4#!K2"O"  E4OQWC55[+_'U9@]-+D5[@WDDV<#)R?4V;3L^N:[AQC?.
M]:87:C<P=JJX1 6A8 (L@ OL1(B;$L157ZD:M@*I$"VQW 72*TGXHQ>AC+&A
M?$T5!XL4;I)1X@'8V)J:M;C$3J!7#<,9 (@)=4%>8Z0TYLK& G;3EF6IM9N/
MRS6G^S0P;W4M)EDQ(1G*)X[@Q'FSM9\L;>E,QYB8&_>(UN6V@X04^ZSM%-?@
M^_H$ C#46>]T-+T1950J;<$$%A:8%F&*%;:%M55W2ZS$%,3!UC[5!PD(BKZF
MT,8QU>?A><=L^K++; -K.5;;.K._#Q]1XD-9@*8N;,;D>KX^L5QN!]F9HB>B
M 901,>LB:N'VEDZ9>.BX7:9 @#3?''BZ%BL_6/7D8*8&]_@88&M4")? T#:>
M5#H[+.04>F9TYR!H:XB9YX 9.6Y,H&)&UU5-GEQ^0KYM[;=+8Q9^=HYIB7EU
MPR2]!;RFF&AMJIRRE? )<!IL7J_)*E$Q.06,6;E1L^32UDZ3M=]S@1&"WK+Y
M 3YW]ED0)HD;(LZ\\-4"?^_/0*K%5:$L:I^HL>WRBJ="O,2@:L.^ /[OZ1 6
M7PK7=\4O?'ZW@2V"S.9MVRW(5';3$4-?"\>V4=4)1>O/9U^D/N.T3/&;Z*^3
MK%/,)2KXD0&:PTYY'K9M;+J/<O(S[P,FHRX-'TMP'S _\\?YXG=M8JL=XON"
M;>L,KPTX[+HTZY9<0J3JNZE/T .21U3C<%@;!V+W]/1^>:';%SF%=IS8/,AL
M[9^AN?JA<I@)MWEPHP:!']VT,X_(YB([3G,V7+8>\TK>8^AK37H#M#MTSKCG
MYBRYEJUFQYVA/*Q;<UNDT(I>7JD=IS\7-%NOFUP/B8!S=%E/KXJ@REG9F4%X
MQ[DU091.Z9O**8U=#5UXH=Z'",_ ]D)M96<*PJ5H4$YG+E+#CI-?"LQTC_AG
MY1Z!6 @]++5A_K?+UA\X:-ZIR2^ZXSY0#+YT\M]6OPNTKG[TH$/STDQVF6?'
M=P*P=*)/;"3Z2L"84"\*8HL(UF1>[$&+A3V@4&7/SC6*06Q8W3FPT6E6'JY3
M>F"(RCT[5U@#SL!Z]8MZJ;JO/+*G#.^K19\C]6OP&=BO?IU/6[[R9/ ^2"6H
MJ[<[YT\.3[X1D[P"0;FWCL#BVDMGZ@X)NX4^4= 9#, U+1AL6(FJCRE4 GG<
M9\ML4-FZ%V&P06=G\C&[WVD5_'"8$F#;NJ-AL.&",H)#PL,=)JV"'PY3 FQ;
M=T?FUO4&<8M[[%'8&CSK*5IZ]B[X)/39NE&#TXQ%BMMT45\!QH?(FS9OBU=@
MY^F:C($_L5%; J@"J4\U\_0U(PH>Q<@OMUO</NBX1464"NX">.$UD6N,-KU!
MZ1Y<HH;MIKD,5+8F%W$CNE(&^CO<>H/\IR/EE[.3VXPTV\2M 19;)Z11]+G@
MH@_C0&#6(8M1FE]PNSDM (R]<7FA?&_0IMIXYN4-KG')G> M87J!>%I_\MLM
M;2I=G\M C_#+S3C]9:]>H(>#Y7>W+9YXWM8/\_+E0R^S/+"UC=Q=>:!N6_3M
M@!M64']AB43XPJ<#A7>Z]%,:Q"1C#R2_9.67SM?13_VNPRSC;1UVE\I_Y>*;
MWH+%!,)X:<@@O"W\K)AHZTKK4M\^N?M(% A*_%Q&$K+;0DC2P!)S#=/0N'A?
M_]+?\?W^Y?\!4$L#!!0    ( ,& "5END)A,M D  $%S   5    =71M9"TR
M,#(T,#8S,%]D968N>&UL[5UK<QHY%OV<_ HF^X&=JF#\&&=C5YPI@NT4LXY-
MX7@RNUM;4Z(E0)-&(I+:-O]^K_IAVG2K:4#]()LO#H_;5^>>HY;N%5+GW:^/
M4[=Q3X2DG)TU#_;VFPW"'(XI&Y\UJ>2MMV^/3UH'S5_?OWSW4ZO5Z N./8?@
MQG#>N#C_V!E(CRK2D'RD'I @KQL=?(^8-NCRZ<Q31#1ZC/%[I* !^1K>.'NO
MX;O97-#Q1#7^WOVY<;B__[9UN'_X2^,__?X?_SRY/K\Z^NW?7WZ_.-J__.WV
MS7_W&@\/#WL$CY'P6]MS^+31:@$BE[*OI_K/$$G2@%"8/'LU46IVVF[K:QZ'
MPMWC8MR&)H[:D>&KER]>^+:GCY(^LW\XBJP/VG]\NKIU)F2*6I1)I6/RKY/T
M5/H?7W''#RI'@PVCA7[7BLQ:^J/6P6'KZ&#O4>(%S!%UG[7B*329$JQY:&O>
M]M\<[2^LM;OU6$A<$?)P<')RTO:_C1F#,ZR>K..^C]O!E\^-:0:6)V;?OWP1
MB(F$([A+!F34"%_>#7K)UBA3;4RG[="FC5SW5<-'>JKF,W+V2M+IS"719Q-!
M1D88$6Q-_[$F_F_:6WM;2!/ (1QO2%KP*6'Z!K,(,<W[UI"?7+4P&2'/518!
M)WW;A,NGB-JD-^%Z>["^G]:43(=$V$3ZS.\"9H1Q&:!I_&C[*"D6?YYSQX/H
M5?1OA^$+IJB:]]B(BZD_Z*T.P%-3W(J<^TAS^UX$ 5V%,JH_O(*WS]HDCXHP
M3'#4JH9O.T@;;-XJI(ANX0[,/A%,'>0&DZB2,!EV85;D+L5@A#\@5P^&MQ-"
M<MQYZ01OVEP9G&^/K709^I#3,#4A2MN7K,GSMFLLD EH*6H]F=Z,X!L^)26H
ME&RS9NID :Q&E;)OI!4 ZJY776ZI6\6=KQ/N8J@0+[Y!\34O5[N4]NLK70I8
MP!J"=;D31]AT=?G(13-.75,#E%$6.4)RZ.=]GFR-$9KY.-O$53+ZQ&?99SC\
M8 '\,QJZ)'+NHB%QSYH&HW9E( .2]$(!9_!6=AZI7(4Y]9I8"(M.T1'/@X%,
M/'(>)N5!+&L6<9&/D>!3(Z=1PSQO! U/ AP^T\"1VVQP ;TH7) )4OY3AS,%
M_?K"];V<-249ZQ?EZ[<4P+E?@1AT2[<M3*_ENFV%6%D=,*Z=(6*S9KNGR9\'
MI:@2U/Y%R@*![-+-!.BGG/E3QR>_AC>(EK0K3J[XDD*Z5)G=+2Y12G@UNFLZ
M&-, 1Q]1W&-=-*,*N9E"9%^S$Z*L"#M=H,,J!-+!"#+1H\<]"5+C57>)P7XG
MA,D(-UV4HRI$&1 %^ F^0()1-I:9BAB,=T(.4Z#I6OQ2A19/<R:40*0'+U<F
MT O#PC1 KKMBAD^@3<V4PUPZY'=_[W@Q?;M<$GS65,(C*^?T);TJT&BY+H1;
MV_7T;ZQ]+GS2E1)T"#4IQ/N97W.F0P$J <6X!T$)(I515RO.J[P?\_8*.RS6
M*/VXG2# =.,I_2NH#L2D<<)N!^1*QE:CO,+O3#TI/8+//:&[$!&4X]^1ZQ'_
MNQL?IKQXA/*?PE"3=?>MY6<'E%N?FQHE)P;T07>T(&V6HYW5-I,=>]E.<F5X
M1-UXB3@@#H',%W<8AMR+"H+O($>+L(0KK"'")=FV\51?W;;B)UVXXZJ%"SJ;
M/?E"?]^EB!%7Z5*^J6R #>#U702X9U"NFG]J2#6NKU:KHDP7XA^5"3$@,T\X
M$R3C_2DQ;6>ID]/#CDB6EX]T'=_65\?447,C%]^+DMECXTD54MZH"1$IBWA7
M7,I++@@=LZXG!&'._+- 3"+'YYYA_YWK[SKKX+\\J31'UT3=C#ZC1X/H!356
M_^Y1%,N&E8']*GK2.;VGF# L8XE#%\F)H2\8S>NOICE2@QZ5+-7T!1]1I7N8
M08&80?TYCT=C8#E:EGG77@H$''\M=S\2O,8Z^XKOM=$]Y-+E#R5L1\ILOF:[
MD7)BW6)S.)5Z[=T3Y .25-Z,^C '0S/;[0K/=%K*=O"<"&P0=TT>.H[#/:9T
M*B,X@Y>.KY6$.:H[06Q,0->X#64.!2[E]@1OTWBY0MA!:D.P'KN'5KF@-@2(
M.RN7T/26;1#DS]D?=*:NLS(8?RR-!@:_Y=*V$H0-!K\@ ;FIF@]@U!'W&^]A
M-SLLES-SZS;(&A#HR![\X_!Q$,GV?*7X+)>R3  V6.M*"F^"7TAU/CH6Q!]-
M^V&5O;#<GLTUVBJ7Y8V V6 _VD+2)\)?M]B>XX3'<IG,:-[*E.(-)?GFZ<V@
M>M:R,/$F/)8\C9B;KSBIS+BT#W6%,_?_6DE^2D&Y,VGJ)B%9SF?U$PZPYQ)]
M[BCX<!XLG05[K^SFNRL;JRP?7@-9,0G, D#XG?PP#TO\+A3R8P!D2Y!M&J\Z
M)=H$:1&S]P+'\C=Z^<"!&_^<NIXBV)9HVP*H-C?8'&UIP]VYWNKKEC7>1:W5
M<,!+0BMNA< :Z=GNZ[!>4 RM2W6V-3X-?BM=1"B&P8WF&&L\;]7Z#DS&$=3_
MGV/04J@80'BW  =O%FU^)'PLT&RB?\M).?:<;5OGX\XKHJSZ9.8J?8+&XKA3
MC])FVU9TO#E7!WO2R!QIT2<DRM"@PN/,=F0H]QAS^@9?0$*DHLY=^A&_5),J
M-C_DZC713MQD4/;Z>SJ-^A ,Q22#Q66+VI.8"*GHLSTKQHPP[[@1MY J4H<8
MIM14L[K/INFQF0FOQ40:[4^!VCZ$+8V#N-FVPHDTJT<M*9,69,5SJ!7Z*YY#
MMU*@#M/GS5 JH@1U,@;^99.J1OZ5'>9IY$\$5?3T^7'.H.AT^7@..CE*Z')T
M3,3\3O@?&KG-=UWM"<\9OKT).%V%:P*.3<]&23&H/:_+ =D[PYI.X >7<ZRW
M%>K5E$\<".'Z+ /@[#@ 4OKKLD9VU[FZ]M2O1<6/AVW\>-C&6@^G\=<B+X&*
MKG[\ W+4%ZHF74\J*/S$Q6/XS(B.E-#3]$].IO,UFWBJ_];_C?C)GN*+.B*P
MR;8M:TOSZS=9UYULW_,BO&'=*D;,0/\W([+C?/.H#.[&Y-) OFOJO$Z0,^JJ
M*Z),B*D%:MZK*EHI6*NWY1+*_@)"R5)4N&I0E!IU6$SH<@ZCA*[]]*ILCSG&
M4L%D645NLF9/6SPMPQ!LG1[>]:,8J'TQ<*FI):Y^VDJ/*<3&%,+2F6W8!P7!
M!P;5<EU:_W0_'P-%3S8#HL.!JN)?! EY,_*K#'UP_^XV.3I<<G%)IHY^N,,E
MY*T32KHNG=W.)<28,MS9\UU?-2USF+U66'PYM_'^4&O5W=8(=F1#;4&[.9?.
MLMC;QVEP7.U1G1B*\-[0?_3_H?C^Y?\ 4$L#!!0    ( ,& "5DK@<82GB<
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MW>2&>20^HCU3=,CU! F.EF >JJ>JL1ZPP,=&,CLPBD[8N^!5/L8/77\3X!B
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M GG(5(""SF++WXD?<<!HW#1@[(MR5H!>,@Y NX/@,E;H,_+]WP)R']P@AY$
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M^N#.G6"&@)V<E6*6P)PW#=@*UUF >1Z$2&B+5VCLA$ZR*J@(?2K%#8=>;2I
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ME;*UASJB8L< /9UWE^,B<3H/17,4,+Q"L;N^((R]1U-"A>,NII?O7H^=;.Z
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M '_G+""!X23 :.(8B@R?Z'KBS'1ZC5'_D5 :^FB-E^J@W2C_,?@.4$L#!!0
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M16_?G#6;?L>(BO"M?6ITC@%Q1T+ET/#=3Y *93>05#&1 .4)XRNX+#F%EN^
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M+3(P,C0P-C,P+FAT;5!+ 0(4 Q0    ( ,& "5G%BG4;C @  ,1&   1
M          "  02G  !U=&UD+3(P,C0P-C,P+GAS9%!+ 0(4 Q0    ( ,&
M"5GR( [SMPD  .%]   5              "  ;^O  !U=&UD+3(P,C0P-C,P
M7V-A;"YX;6Q02P$"% ,4    " #!@ E9;I"83+0)  !!<P  %0
M    @ &IN0  =71M9"TR,#(T,#8S,%]D968N>&UL4$L! A0#%     @ P8 )
M62N!QA*>)P  V_$! !4              ( !D,,  '5T;60M,C R-# V,S!?
M;&%B+GAM;%!+ 0(4 Q0    ( ,& "5DS_G>M;!@  $:+ 0 5
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9:'1M4$L%!@     *  H ?@(  "H; 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>utmd-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:fil="http://www.utahmed.com/20240630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20240630.xsd" xlink:type="simple"/>
    <context id="D240101_240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="E24Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E23Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="I240808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="E23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Y24Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y23Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="D230101_230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="E22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Y24Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="E24Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Y24Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="E24Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E22_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Y23Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="E23Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Y23Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Y23Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Y23Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Y23Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="E23Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="E23Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="E23Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="E23Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="D240101_240630_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D240701_240808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="D240101_240630" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="D240101_240630" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="D240101_240630" id="fact3">Yes</dei:EntityCurrentReportingStatus>
    <dei:AmendmentFlag contextRef="D240101_240630" id="fact4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="D240101_240630" id="fact5">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="D240101_240630" id="fact6">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="D240101_240630" id="ixv-5768">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="D240101_240630" id="ixv-5769">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="D240101_240630" id="ixv-5770">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="D240101_240630" id="ixv-5771">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="D240101_240630" id="ixv-5772">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="D240101_240630" id="ixv-5773">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D240101_240630" id="ixv-5774">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="D240101_240630" id="ixv-5775">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D240101_240630" id="ixv-5776">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D240101_240630" id="ixv-5777">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D240101_240630" id="ixv-5778">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D240101_240630" id="ixv-5779">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D240101_240630" id="ixv-5780">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D240101_240630" id="ixv-5781">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="D240101_240630" id="ixv-5782">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D240101_240630" id="ixv-5783">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D240101_240630" id="ixv-5784">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityInteractiveDataCurrent contextRef="D240101_240630" id="ixv-5785">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="D240101_240630" id="ixv-5786">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="D240101_240630" id="ixv-5787">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="D240101_240630" id="ixv-5788">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="D240101_240630" id="ixv-5789">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I240808"
      decimals="INF"
      id="ixv-5790"
      unitRef="Shares">3477117</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5791"
      unitRef="USD">89219000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E23" decimals="-3" id="ixv-5792" unitRef="USD">92868000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5793"
      unitRef="USD">3668000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E23" decimals="-3" id="ixv-5794" unitRef="USD">3391000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5795"
      unitRef="USD">9058000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E23" decimals="-3" id="ixv-5796" unitRef="USD">9582000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5797"
      unitRef="USD">377000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E23" decimals="-3" id="ixv-5798" unitRef="USD">428000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5799"
      unitRef="USD">102322000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E23" decimals="-3" id="ixv-5800" unitRef="USD">106269000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5801"
      unitRef="USD">10194000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E23" decimals="-3" id="ixv-5802" unitRef="USD">10551000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5803"
      unitRef="USD">13640000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E23" decimals="-3" id="ixv-5804" unitRef="USD">13692000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5805"
      unitRef="USD">54030000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E23" decimals="-3" id="ixv-5806" unitRef="USD">54296000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5807"
      unitRef="USD">50154000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E23" decimals="-3" id="ixv-5808" unitRef="USD">49350000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5809"
      unitRef="USD">3876000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E23" decimals="-3" id="ixv-5810" unitRef="USD">4946000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5811"
      unitRef="USD">130032000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E23" decimals="-3" id="ixv-5812" unitRef="USD">135458000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5813"
      unitRef="USD">834000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E23" decimals="-3" id="ixv-5814" unitRef="USD">769000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5815"
      unitRef="USD">3105000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E23" decimals="-3" id="ixv-5816" unitRef="USD">3941000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5817"
      unitRef="USD">3939000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E23" decimals="-3" id="ixv-5818" unitRef="USD">4710000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5819"
      unitRef="USD">860000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E23" decimals="-3" id="ixv-5820" unitRef="USD">1120000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5821"
      unitRef="USD">698000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E23" decimals="-3" id="ixv-5822" unitRef="USD">698000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5823"
      unitRef="USD">275000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E23" decimals="-3" id="ixv-5824" unitRef="USD">295000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5825"
      unitRef="USD">208000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E23" decimals="-3" id="ixv-5826" unitRef="USD">322000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5827"
      unitRef="USD">5980000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E23" decimals="-3" id="ixv-5828" unitRef="USD">7145000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E24Q2"
      decimals="INF"
      id="ixv-5829"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E23"
      decimals="INF"
      id="ixv-5830"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5831"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E23"
      decimals="-3"
      id="ixv-5832"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5833"
      unitRef="Shares">3499000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5834"
      unitRef="Shares">3499000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="E23"
      decimals="-3"
      id="ixv-5835"
      unitRef="Shares">3630000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E23"
      decimals="-3"
      id="ixv-5836"
      unitRef="Shares">3630000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5837"
      unitRef="USD">35000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E23" decimals="-3" id="ixv-5838" unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5839"
      unitRef="USD">-11322000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E23" decimals="-3" id="ixv-5840" unitRef="USD">-10658000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5841"
      unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E23" decimals="-3" id="ixv-5842" unitRef="USD">594000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5843"
      unitRef="USD">135339000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E23" decimals="-3" id="ixv-5844" unitRef="USD">138341000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5845"
      unitRef="USD">124052000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E23" decimals="-3" id="ixv-5846" unitRef="USD">128313000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5847"
      unitRef="USD">130032000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E23" decimals="-3" id="ixv-5848" unitRef="USD">135458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5849"
      unitRef="USD">10400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5850"
      unitRef="USD">12866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5851"
      unitRef="USD">21740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5852"
      unitRef="USD">25386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5853"
      unitRef="USD">4147000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5854"
      unitRef="USD">5127000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5855"
      unitRef="USD">8722000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5856"
      unitRef="USD">9805000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5857"
      unitRef="USD">6253000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5858"
      unitRef="USD">7739000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5859"
      unitRef="USD">13018000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5860"
      unitRef="USD">15581000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5861"
      unitRef="USD">2560000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5862"
      unitRef="USD">3181000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5863"
      unitRef="USD">5176000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5864"
      unitRef="USD">6440000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5865"
      unitRef="USD">255000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5866"
      unitRef="USD">133000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5867"
      unitRef="USD">521000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5868"
      unitRef="USD">277000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5869"
      unitRef="USD">2815000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5870"
      unitRef="USD">3314000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5871"
      unitRef="USD">5697000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5872"
      unitRef="USD">6717000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5873"
      unitRef="USD">3438000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5874"
      unitRef="USD">4425000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5875"
      unitRef="USD">7321000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5876"
      unitRef="USD">8864000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5877"
      unitRef="USD">773000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5878"
      unitRef="USD">747000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5879"
      unitRef="USD">1689000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5880"
      unitRef="USD">1428000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5881"
      unitRef="USD">4211000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5882"
      unitRef="USD">5172000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5883"
      unitRef="USD">9010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5884"
      unitRef="USD">10292000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5885"
      unitRef="USD">758000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5886"
      unitRef="USD">972000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5887"
      unitRef="USD">1601000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5888"
      unitRef="USD">1878000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5889"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5890"
      unitRef="USD">4200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5891"
      unitRef="USD">7409000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5892"
      unitRef="USD">8414000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-5893"
      unitRef="UsdPerShare">0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y23Q2"
      decimals="INF"
      id="ixv-5894"
      unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-5895"
      unitRef="UsdPerShare">2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D230101_230630"
      decimals="INF"
      id="ixv-5896"
      unitRef="UsdPerShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-5897"
      unitRef="UsdPerShare">0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y23Q2"
      decimals="INF"
      id="ixv-5898"
      unitRef="UsdPerShare">1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-5899"
      unitRef="UsdPerShare">2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D230101_230630"
      decimals="INF"
      id="ixv-5900"
      unitRef="UsdPerShare">2.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5901"
      unitRef="Shares">3532000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5902"
      unitRef="Shares">3628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5903"
      unitRef="Shares">3579000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5904"
      unitRef="Shares">3628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5905"
      unitRef="Shares">3532000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5906"
      unitRef="Shares">3639000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5907"
      unitRef="Shares">3579000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5908"
      unitRef="Shares">3638000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-5909"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y23Q2"
      decimals="INF"
      id="ixv-5910"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-5911"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="D230101_230630"
      decimals="INF"
      id="ixv-5912"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5913"
      unitRef="USD">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5914"
      unitRef="USD">504000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5915"
      unitRef="USD">-664000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5916"
      unitRef="USD">1053000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-5917"
      unitRef="USD">3420000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-5918"
      unitRef="USD">4704000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5919"
      unitRef="USD">6745000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5920"
      unitRef="USD">9467000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5921"
      unitRef="USD">7409000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5922"
      unitRef="USD">8414000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5923"
      unitRef="USD">327000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5924"
      unitRef="USD">310000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5925"
      unitRef="USD">1023000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5926"
      unitRef="USD">3207000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5927"
      unitRef="USD">-6000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5928"
      unitRef="USD">-26000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5929"
      unitRef="USD">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5930"
      unitRef="USD">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5931"
      unitRef="USD">-364000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5932"
      unitRef="USD">-137000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5933"
      unitRef="USD">131000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5934"
      unitRef="USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5935"
      unitRef="USD">20000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5936"
      unitRef="USD">9000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5937"
      unitRef="USD">297000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5938"
      unitRef="USD">-2044000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5939"
      unitRef="USD">-441000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5940"
      unitRef="USD">1245000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5941"
      unitRef="USD">-45000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5942"
      unitRef="USD">-3000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5943"
      unitRef="USD">66000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5944"
      unitRef="USD">114000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5945"
      unitRef="USD">-783000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5946"
      unitRef="USD">-991000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5947"
      unitRef="USD">629000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5948"
      unitRef="USD">3414000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5949"
      unitRef="USD">8038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5950"
      unitRef="USD">11828000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5951"
      unitRef="USD">132000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5952"
      unitRef="USD">363000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5953"
      unitRef="USD">5000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5954"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5955"
      unitRef="USD">27000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5956"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5957"
      unitRef="USD">-110000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5958"
      unitRef="USD">-363000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5959"
      unitRef="USD">390000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5960"
      unitRef="USD">81000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5961"
      unitRef="USD">9393000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5962"
      unitRef="USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5963"
      unitRef="USD">2170000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5964"
      unitRef="USD">2140000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5965"
      unitRef="USD">-11173000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5966"
      unitRef="USD">-2059000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5967"
      unitRef="USD">-404000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5968"
      unitRef="USD">161000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5969"
      unitRef="USD">-3649000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5970"
      unitRef="USD">9567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E23" decimals="-3" id="ixv-5971" unitRef="USD">92868000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E22" decimals="-3" id="ixv-5972" unitRef="USD">75052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-5973"
      unitRef="USD">89219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E23Q2"
      decimals="-3"
      id="ixv-5974"
      unitRef="USD">84619000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5975"
      unitRef="USD">2791000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5976"
      unitRef="USD">2546000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaid
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-5977"
      unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-5978"
      unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:SharesOutstanding
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5979"
      unitRef="Shares">3630000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5980"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5981"
      unitRef="USD">593000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5982"
      unitRef="USD">-10658000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5983"
      unitRef="USD">138341000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E23" decimals="-3" id="ixv-5984" unitRef="USD">128313000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5985"
      unitRef="Shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5986"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5987"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5988"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5989"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5990"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5991"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5992"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5993"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5994"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5995"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5996"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5997"
      unitRef="Shares">43000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5998"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5999"
      unitRef="USD">-769000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6000"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6001"
      unitRef="USD">-2221000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-6002"
      unitRef="USD">-2990000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6003"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6004"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6005"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6006"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6007"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-6008"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6009"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6010"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6011"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6012"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6013"
      unitRef="USD">1081000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-6014"
      unitRef="USD">1081000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6015"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6016"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6017"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6018"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6019"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-6020"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6021"
      unitRef="Shares">3588000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6022"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6023"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6024"
      unitRef="USD">-11289000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6025"
      unitRef="USD">138995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-6026"
      unitRef="USD">127742000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6027"
      unitRef="Shares">6000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6028"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6029"
      unitRef="USD">294000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6030"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6031"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6032"
      unitRef="USD">294000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6033"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6034"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6035"
      unitRef="USD">52000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6036"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6037"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6038"
      unitRef="USD">52000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6039"
      unitRef="Shares">95000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6040"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6041"
      unitRef="USD">-346000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6042"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6043"
      unitRef="USD">-6056000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6044"
      unitRef="USD">-6403000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6045"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6046"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6047"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6048"
      unitRef="USD">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6049"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6050"
      unitRef="USD">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6051"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6052"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6053"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6054"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6055"
      unitRef="USD">1052000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6056"
      unitRef="USD">1052000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6057"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6058"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6059"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6060"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6061"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6062"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6063"
      unitRef="Shares">3499000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6064"
      unitRef="USD">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6065"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6066"
      unitRef="USD">-11322000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6067"
      unitRef="USD">135339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-6068"
      unitRef="USD">124052000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E22_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6069"
      unitRef="Shares">3628000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6070"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6071"
      unitRef="USD">251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6072"
      unitRef="USD">-12039000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6073"
      unitRef="USD">126006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E22" decimals="-3" id="ixv-6074" unitRef="USD">114254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6075"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6076"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6077"
      unitRef="USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6078"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6079"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-6080"
      unitRef="USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6081"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6082"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6083"
      unitRef="USD">50000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6084"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6085"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-6086"
      unitRef="USD">50000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6087"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6088"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6089"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6090"
      unitRef="USD">549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6091"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-6092"
      unitRef="USD">549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6093"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6094"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6095"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6096"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6097"
      unitRef="USD">1070000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-6098"
      unitRef="USD">1070000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6099"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6100"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6101"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6102"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6103"
      unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-6104"
      unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6105"
      unitRef="Shares">3628000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6106"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6107"
      unitRef="USD">322000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6108"
      unitRef="USD">-11491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6109"
      unitRef="USD">129150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q1"
      decimals="-3"
      id="ixv-6110"
      unitRef="USD">118018000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6111"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6112"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6113"
      unitRef="USD">60000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6114"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6115"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6116"
      unitRef="USD">60000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6117"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6118"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6119"
      unitRef="USD">50000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6120"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6121"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6122"
      unitRef="USD">50000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6123"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6124"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6125"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6126"
      unitRef="USD">504000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6127"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6128"
      unitRef="USD">504000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6129"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6130"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6131"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6132"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6133"
      unitRef="USD">1071000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6134"
      unitRef="USD">1071000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6135"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6136"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6137"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6138"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6139"
      unitRef="USD">4200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6140"
      unitRef="USD">4200000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6141"
      unitRef="Shares">3629000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6142"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6143"
      unitRef="USD">432000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6144"
      unitRef="USD">-10986000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6145"
      unitRef="USD">132279000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23Q2"
      decimals="-3"
      id="ixv-6146"
      unitRef="USD">121761000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="D240101_240630" id="ixv-2897">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2023. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="D240101_240630" id="ixv-2900">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
 &lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D240101_240630" id="ixv-2902">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="D240101_240630" id="ixv-2906">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;(3) Inventories at June 30, 2024 and December 31, 2023 consisted of the following:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:172.9pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; June 30, 2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2023&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,334&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,685&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:172.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:130.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,435&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:122.45pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,503&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,289&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,394&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:172.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,058&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,582&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D240101_240630" id="ixv-2908">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:172.9pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; June 30, 2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2023&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,334&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,685&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:172.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:130.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,435&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:122.45pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,503&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:172.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:16.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:130.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,289&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:16.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:122.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,394&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:172.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:130.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,058&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:122.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,582&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-6147"
      unitRef="USD">1334000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E23" decimals="-3" id="ixv-6148" unitRef="USD">1685000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-6149"
      unitRef="USD">1435000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E23" decimals="-3" id="ixv-6150" unitRef="USD">1503000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-6151"
      unitRef="USD">6289000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E23" decimals="-3" id="ixv-6152" unitRef="USD">6394000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-6153"
      unitRef="USD">9058000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E23" decimals="-3" id="ixv-6154" unitRef="USD">9582000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D240101_240630" id="ixv-2975">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(4) Stock-Based Compensation. At June 30, 2024, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2024 and 2023, the Company recognized $52 and $50, respectively, in stock based compensation cost. &#160;In the six months ended June 30, 2024 and 2023, the Company recognized $131 and $100, respectively, in stock based compensation expense.&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6155"
      unitRef="USD">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6156"
      unitRef="USD">50000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6157"
      unitRef="USD">131000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-6158"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="D240101_240630" id="ixv-2979">&lt;p style="font:10pt Times New Roman;margin:0"&gt; (5) Warranty Reserve. &#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2023 or June 30, 2024. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="E23" decimals="INF" id="ixv-6159" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="E24Q2"
      decimals="INF"
      id="ixv-6160"
      unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D240101_240630" id="ixv-2984">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(6) Global 2Q 2024 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;852&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;167&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,019&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,410&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,042&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,452&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,231&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;315&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,546&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,338&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,045&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,383&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,831&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,569&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,400&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 1H 2024 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,656&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;388&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,044&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,762&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,150&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,912&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,477&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;711&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,188&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,127&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,469&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,596&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,022&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,718&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;21,740&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleOfRevenuesByProductCategoryTextBlock contextRef="D240101_240630" id="ixv-2986">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;852&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;167&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,019&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,410&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,042&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,452&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,231&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;315&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,546&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,338&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,045&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,383&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,831&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,569&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,400&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 1H 2024 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,656&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;388&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,044&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,762&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,150&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,912&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,477&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;711&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,188&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,127&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,469&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,596&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,022&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,718&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;21,740&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</fil:ScheduleOfRevenuesByProductCategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6161"
      unitRef="USD">852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6162"
      unitRef="USD">167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-Obstetrics"
      decimals="-3"
      id="ixv-6163"
      unitRef="USD">1019000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6164"
      unitRef="USD">2410000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6165"
      unitRef="USD">3042000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      id="ixv-6166"
      unitRef="USD">5452000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6167"
      unitRef="USD">1231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6168"
      unitRef="USD">315000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-Neonatal"
      decimals="-3"
      id="ixv-6169"
      unitRef="USD">1546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6170"
      unitRef="USD">1338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6171"
      unitRef="USD">1045000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      id="ixv-6172"
      unitRef="USD">2383000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6173"
      unitRef="USD">5831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6174"
      unitRef="USD">4569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6175"
      unitRef="USD">10400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6176"
      unitRef="USD">1656000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6177"
      unitRef="USD">388000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-Obstetrics"
      decimals="-3"
      id="ixv-6178"
      unitRef="USD">2044000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6179"
      unitRef="USD">4762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6180"
      unitRef="USD">6150000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      id="ixv-6181"
      unitRef="USD">10912000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6182"
      unitRef="USD">2477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6183"
      unitRef="USD">711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-Neonatal"
      decimals="-3"
      id="ixv-6184"
      unitRef="USD">3188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6185"
      unitRef="USD">3127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6186"
      unitRef="USD">2469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      id="ixv-6187"
      unitRef="USD">5596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-6188"
      unitRef="USD">12022000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-6189"
      unitRef="USD">9718000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6190"
      unitRef="USD">21740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="D240101_240630" id="ixv-3250">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#xae; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of expenses over the 4.75 year remaining life of the CSI distribution agreement with Femcare Ltd which ended in October 2023.&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="-3"
      id="ixv-6191"
      unitRef="USD">21000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem
      contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="INF"
      id="ixv-6192"
      unitRef="Pure">4.75</fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem>
    <us-gaap:EarningsPerShareTextBlock contextRef="D240101_240630" id="ixv-3254">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2024.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:151.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:151.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Six months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:151.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:151.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,453&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,200&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,409&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,414&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,532&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,628&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,579&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,628&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,532&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,639&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,579&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,638&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.98&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.16&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.07&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.32&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.98&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.15&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.07&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.31&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D240101_240630" id="ixv-3257">&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:151.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:151.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Six months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:151.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:151.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,453&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,200&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,409&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,414&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,532&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,628&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,579&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,628&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,532&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,639&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,579&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,638&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.98&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.16&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.07&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:70.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.32&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:159.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.98&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.15&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.55pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.07&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:10.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:70.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.31&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6193"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6194"
      unitRef="USD">4200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6195"
      unitRef="USD">7409000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-6196"
      unitRef="USD">8414000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6197"
      unitRef="Shares">3532000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6198"
      unitRef="Shares">3628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6199"
      unitRef="Shares">3579000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-6200"
      unitRef="Shares">3628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6201"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6202"
      unitRef="Shares">11000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6203"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-6204"
      unitRef="Shares">10000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6205"
      unitRef="Shares">3532000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y23Q2"
      decimals="-3"
      id="ixv-6206"
      unitRef="Shares">3639000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6207"
      unitRef="Shares">3579000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D230101_230630"
      decimals="-3"
      id="ixv-6208"
      unitRef="Shares">3638000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-6209"
      unitRef="UsdPerShare">0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y23Q2"
      decimals="INF"
      id="ixv-6210"
      unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-6211"
      unitRef="UsdPerShare">2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D230101_230630"
      decimals="INF"
      id="ixv-6212"
      unitRef="UsdPerShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-6213"
      unitRef="UsdPerShare">0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y23Q2"
      decimals="INF"
      id="ixv-6214"
      unitRef="UsdPerShare">1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-6215"
      unitRef="UsdPerShare">2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D230101_230630"
      decimals="INF"
      id="ixv-6216"
      unitRef="UsdPerShare">2.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock contextRef="D240101_240630" id="ixv-3468">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(9) Subsequent Events.&lt;b&gt; &#160;&lt;/b&gt;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements&lt;b&gt;.  &lt;/b&gt;After June 30, 2024 through August 8, 2024, the Company made additional repurchases of 21,785 shares of its stock in the open market for $1,441, at an average price of $66.15 per share.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="D240701_240808"
      decimals="INF"
      id="ixv-6217"
      unitRef="Shares">21785</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D240701_240808"
      decimals="-3"
      id="ixv-6218"
      unitRef="USD">1441000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="D240701_240808"
      decimals="INF"
      id="ixv-6219"
      unitRef="UsdPerShare">66.15</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
